(54) Title: VARIANTS OF SOLUBLE PYRROLOQUINOLINE QUINONE-DEPENDENT GLUCOSE DEHYDROGENASE

Schematic diagram of the plasmide with gene for s-GDH (pACSGDH)

(57) Abstract: The present invention relates to improved variants of soluble pyrroloquinoline quinone (PQQ)-dependent glucose dehydrogenases (s-GDH), to genes encoding mutated s-GDH, to mutant proteins of s-GDH with improved substrate specificity for glucose, and to different applications of these s-GDH variants, particularly for determining concentrations of sugar, especially of glucose in a sample.

WO 02/34919 A1

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,* *YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

Published:

— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

VARIANTS OF SOLUBLE PYRROLOQUINOLINE QUINONE-DEPENDENT GLUCOSE DEHYDROGENASE

The present invention relates to improved variants of soluble pyrroloquinoline quinone (PQQ)-dependent glucose dehydrogenases (s-GDH), to genes encoding mutated s-GDH, to mutant proteins of s-GDH with improved substrate specificity for glucose, and to different applications of these s-GDH variants, particularly for determining concentrations 5 of sugar, especially of glucose in a sample.

Two types of PQQ-dependent glucose dehydrogenase (EC 1.1.99.17) have been characterized: One is membrane-bound (m-GDH), the other is soluble (s-GDH). Both types do not share any significant sequence homology (Cleton-Jansen, A. M., et al., Mol Gen Genet 217 (1989) 430-6; Cleton-Jansen, A. M., et al., Antonie Van Leeuwenhoek 56 10 (1989) 73-9; Oubrie, A., et al., Proc Natl Acad Sci U S A 96 (1999) 11787-91). They are also different regarding both their kinetic as well as their immunological properties (Matsushita, K., et al., Bioscience Biotechnology & Biochemistry 59 (1995) 1548-1555).

Quinoproteins use quinone as cofactor to oxidize alcohols, amines and aldoses to their corresponding lactones, aldehydes and aldolic acids (Duine, J. A. Energy generation and the 15 glucose dehydrogenase pathway in Acinetobacter in "The Biology of Acinetobacter" (1991) 295-312, New York, Plenum Press; Duine, J. A., Eur J Biochem 200 (1991) 271-84, Davidson, V. L. - in "Principles and applications of quinoproteins" (1993) the whole book, New York, Marcel Dekker; Anthony, C., Biochem J 320 (1996) 697-711 ;Anthony, C. and Ghosh, M., Current Science 72 (1997) 716-727; Anthony, C., Biochem Soc Trans 26 (1998) 20 413-7; Anthony, C. and Ghosh, M., Prog Biophys Mol Biol 69 (1998) 1-21). Among quinoproteins, those containing the noncovalently bound cofactor 2,7,9-tricarboxy-1H-pyrrolo [2,3-f]quinoline-4,5-dione (PQQ) constitute the largest sub-group (Duine 1991, supra). All bacterial glucose dehydrogenases known so far belong to this sub-group with PQQ as the prosthetic group (Anthony and Ghosh 1997, supra, Goodwin and Anthony 25 1998, supra).

In bacteria, there are two completely different types of PQQ-dependent glucose dehydrogenases (EC1.1.99.17): the soluble type (s-GDH) and the membrane-bound type

(m-GDH) (Duine et al., 1982; Matsushita et al., 1989a,b). The m-GDHs are widespread in Gram-negative bacteria, s-GDHs, however, have been found only in the periplasmatic space of *Acinetobacter* strains, like *A. calcoaceticus* (Duine, 1991a; Cleton-Jansen et al., 1988; Matsushita and Adachi, 1993) and *A. baumannii* (JP 11243949).

5   Through searching sequence databases, two sequences homologous to the full-length *A. calcoaceticus* s-GDH have been identified in *E.coli* K-12 and *Synechocystis sp.*. Additionally, two incomplete sequences homologous to *A. calcoaceticus* s-GDH were also found in the genome of *P.aeruginosa* and *Bordetella pertussis* (Oubrie et al. 1999a), respectively. The deduced amino acid sequences of these four uncharacterized proteins are closely related to
10   *A. calcoaceticus* s-GDH with many residues in the putative active site absolutely conserved. These homologous proteins are likely to have a similar structure and to catalyze similar PQQ-dependent reactions (Oubrie et al., 1999a).

Bacterial s-GDHs and m-GDHs have been found to possess quite different sequences and different substrate specificity. For example, *A. calcoaceticus* contains two different PQQ-
15   dependent glucose dehydrogenases, one m-GDH which is active *in vivo*, and the other designated s-GDH for which only *in vitro* activity can be shown. Cleton-Jansen et al., (1988;1989a,b) cloned the genes coding for the two GDH enzymes and determined the DNA sequences of both these GDH genes. There is no obvious homology between m-GDH and s-GDH corroborating the fact that m-GDH and s-GDH represent two completely
20   different molecules.

The gene of s-GDH from *A. calcoaceticus* has been cloned in *E. coli* behind a leader sequence and a strong promoter. After being synthesized in the cell, the s-GDH is translocated through the cytoplasmic membrane into the periplasmic space (Duine, J. A. Energy generation and the glucose dehydrogenase pathway in *Acinetobacter* in "The Biology
25   of *Acinetobacter*" (1991) 295-312, New York, Plenum Press, Matsushita, K. and Adachi, O. Bacterial quinoproteins glucose dehydrogenase and alcohol dehydrogenase in "Principles and applications of Quinoproteins" (1993) 47-63, New York, Marcel Dekker). Like the native s-GDH from *A. calcoaceticus*, s-GDH expressed in *E.coli* is also a homodimer, with one PQQ molecule and three calcium ions per monomer (Dokter et al., 1986 supra,1987
30   supra1988 supra; Olsthoorn, A. and J. Duine, J. A., Arch Biochem Biophys 336 (1996) 42-8; Oubrie, A., et al., J Mol Biol 289 (1999) 319-33, Oubrie, A., et al., Proc Natl Acad Sci U S A 96 (1999) 11787-91, Oubrie, A., et al., Embo J 18 (1999) 5187-94). s-GDH oxidizes a wide range of mono- and disaccharides to the corresponding ketones which further hydrolyze to

the aldonic acids, and it is also able to donate electrons to PMS (phenazine metosulfate), DCPIP (2,6-dichlorophenolindophenol), WB (Wurster's blue) and short-chain ubiquinones such as ubiquinone Q1 and ubiquinone Q2 (Matsushita, K., et al., Biochemistry 28 (1989) 6276-80; Matsushita, K., et al., Antonie Van Leeuwenhoek 56

5 (1989) 63-72), several artificial electron acceptors such as N-methylphenazonium methyl sulfate (Olsthoorn, A. J. and Duine, J. A., Arch Biochem Biophys 336 (1996) 42-8 ; Olsthoorn, A. J. and Duine, J. A., Biochemistry 37 (1998) 13854-61) and electroconducting polymers (Ye, L., et al., Anal. Chem. 65 (1993) 238-41).

In view of s-GDH's high specific activity towards glucose (Olsthoorn, A. J. and Duine, J. A.,

10 Arch Biochem Biophys 336 (1996) 42-8) and its broad artificial electron acceptor specificity, the enzyme is well suited for analytical applications, particularly for being used in (bio-)sensor or test strips for glucose determination in diagnostic applications (Kaufmann et al., 1997 supra).

Glucose oxidation can be catalyzed by at least three quite distinct groups of enzymes, i.e.,

15 by NAD-dependent, dye-linked glucose dehydrogenases, by flavoprotein glucose oxidase or by quinoprotein GDHs (Duine 1995). A rather slow autooxidation of reduced s-GDH has been observed, demonstrating that oxygen is a very poor electron acceptor for s-GDH (Olsthoorn and Duine 1996). s-GDH can efficiently donate electrons to PMS, DCPIP, WB and short-chain ubiquinones such as Q1 and Q2, but it can not efficiently donate electrons

20 directly to oxygen.

Traditional test strips and sensors for monitoring glucose level in blood, serum and urine e. g. from diabetic patients use glucose oxidase. However, since glucose oxidase transfers its electrons to oxygen, it is known that oxygen may have a negative impact on glucose measurements which are based on this enzyme. The major advantage of PQQ-dependent

25 glucose dehydrogenases is their independence from oxygen. This important feature is e.g., discussed in US 6,103,509, in which some features of membrane-bound GDH have been investigated.

An important contribution to the field has been the use of s-GDH together with appropriate substrates. Assay methods and test strip devices based on s-GDH are disclosed

30 in detail in US 5,484,708. This patent also contains detailed information on the set-up of assays and the production of s-GDH-based test strips for measurement of glucose. The methods described there as well in the cited documents are herewith included by reference.

- 4 -

Other patents or applications relating to the field and comprising specific information on various modes of applications for enzymes with glucose dehydrogenase activity are US 5,997,817; US 6,057,120; EP 620 283; and JP 11-243949-A.

5 A commercial system which utilizes s-GDH and an indicator that produces a color change when the reaction occurs (Kaufmann et al. 1997) is the Glucotrend® system distributed by Roche Diagnostics GmbH.

Despite the above discussed important advantages there also is a major inherent problem of s-GDH. s-GDH has rather a broad substrate spectrum as compared to m-GDH. That is, s-GDH oxidizes not only glucose but also several other sugars including maltose, galactose, 10 lactose, mannose, xylose and ribose (Dokter et al. 1986a). The reactivity towards sugars other than glucose may in certain cases impair the accuracy of determining blood glucose levels, in some diabetic patients. In particular patients on peritoneal dialysis treated with icodextrin (a glucose polymer) may contain in their body fluids, e.g., in blood, high levels of other sugars, especially maltose (Wens, R., et al., Perit Dial Int 18 (1998) 603-9).

15 Therefore clinical samples, as e.g. obtained from diabetic patients, especially from patients with renal complications and especially from patients under dialysis may contain significant levels of other sugars, especially maltose. Glucose determinations in samples obtained from such critical patients may be impaired by maltose.

There are scarce reports in the literature on attempts to produce modified PQQ-dependent 20 s-GDHs which exhibit altered substrate specificity. Due to a negative outcome most of these efforts have not been published. Igarashi, S., et al., (1999) report that introducing a point mutation at position Glu277 leads to mutants with altered substrate specificity profile. However, none of these mutants, lead to an at least two-fold increased improved specificity for glucose as e.g., compared to xylose, galactose or maltose.

25 It can be summarized that the attempts known in the art aiming at improvements of properties of s-GDH, especially its specificity towards glucose, have not been successful to the extend required for accurate monitoring of glucose levels in patients having also high levels of sugars other than glucose.

A great demand and clinical need therefore exists for mutant forms of s-GDH which 30 feature an improved specificity for glucose as substrate.

- 5 -

It was the task of the present invention to provide new mutants or variants of s-GDH with significantly improved substrate specificity for glucose as compared to other selected sugar molecules, e.g., like galactose or maltose.

5   Surprisingly it has been found that it is possible to significantly improve the substrate specificity of s-GDH for glucose, as compared to other sugars, and to at least partially overcome the above described problems known in the art.

The substrate specificity for glucose as compared to other selected sugar molecules has been significantly improved by providing mutant s-GHD according to the present invention as described herein below and in the appending claims. Due to the improved

10 substrate specificity of the new forms of s-GDH, significant technical progress for glucose determinations in various fields of applications is possible.

Summary of the invention:

It has now surprisingly been found that it is possible to provide s-GDH mutants with

15 improved substrate specificity towards glucose as a substrate as compared to other selected sugars. New s-GDH variants are disclosed which exhibit a significant higher substrate specificity for glucose, especially as compared to maltose.

Also disclosed are mutant s-GDH molecules, which, compared to the wild-type enzyme, exhibit essentially equal specific activity for glucose as substrate but markedly reduced

20 activity for other selected sugar molecules.

Such comparison of a mutant's specific activity for one of the various other substrate molecules is based on and calculated in relation to the original enzymatic activities of a wild-type enzyme, e.g., as isolated from *Acinetobacter calcoaceticus*.

Mutated s-GDH proteins as well as polynucleotide-sequences coding for such proteins

25 exhibiting improved properties, especially increased specificity for glucose are also provided.

s-GDH mutants comprising at least one amino acid substitutions at an amino acid position corresponding to a position of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 24) selected from the group consisting of positions 348 and 428 have been

found to provide for s-GDH enzymes with improved properties, especially with improved specificity for glucose. Variants comprising a substitution at position 348 exhibit a strikingly positive effect on glucose specificity.

5 The improved s-GDH mutants can be used with great advantage for the specific detection or measurement of glucose in biological samples, especially in tests strip devices or in biosensors.

The following examples, references, sequence listing and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without 10 departing from the spirit of the invention.

Description of the Figures

Figure 1: Nucleotide (DNA) sequence of the *Acinetobacter calcoaceticus* PQQ dependent soluble glucose dehydrogenase gene and the corresponding amino acid sequence (SEQ ID 15 NO: 23).

Figure 2: Protein sequences of *A. calcoaceticus* PQQ-dependent s-GDH (top) and *A. baumannii* s-GDH (bottom) aligned according to sequence homology.

Figure 3: Illustration of pACSGDH vector referred to in Example 1 containing the wild-type or mutated DNA sequences of soluble PQQ-dependent glucose dehydrogenase.

20 Figure 4: Nucleotide (DNA) sequence of the pACSGDH vector referred to in Example 1 containing the wild-type DNA sequence of soluble PQQ-dependent glucose dehydrogenase (SEQ ID NO: 25).

Detailed description of the invention:
In a first embodiment the invention relates to a mutant of the soluble form of EC 1.1.99.17 25 also known as PQQ-dependent soluble glucose dehydrogenase (s-GDH), said mutant characterized in that relative to the corresponding wild-type enzyme and with regard to at least one other selected sugar substrate, it has an at least two-fold improved substrate specificity for glucose .

- 7 -

The directions given in this invention are easily applied for any known or even yet unknown isolate of s-GDH. These wild-type isolates can be used to assess the relative improvements in specificity for the variants generated therefrom.

The wild-type enzyme of *Acinetobacter calcoaceticus*-type strain LMD 79.41 which

5 corresponds to SEQ ID NO: 24 is well-known and well-characterized. In case a different wild-type enzyme under investigation is not well-characterized it is advantageous to use the s-GDH from *Acinetobacter calcoaceticus*-type strain LMD 79.41 as a reference. In a further preferred embodiment the properties of an improved variant of s-GDH are compared to this wild-type enzyme. The present invention therefore also relates to a mutant of s-GDH

10 said mutant characterized in that relative to the wild-type enzyme of SEQ ID NO: 24 and with regard to at least one other selected sugar substrate, it has an at least two-fold increased substrate specificity for glucose.

As discussed above, two completely different enzyme families with glucose dehydrogenase activity, grouped together under EC1.1.99.17, are characterized to date. These two enzyme

15 families, however, appear not be related to each other.

For the purpose of this invention only the soluble form of GDH (s-GDH) is relevant and improved variants thereof are discussed herein below.

It is known in the art that the wild-type DNA-sequence of a soluble PQQ-dependent glucose dehydrogenase can be isolated from strains of *Acinetobacter*. Most preferred is the

20 isolation from *Acinetobacter calcoaceticus*-type strain LMD 79.41. The sequence of this wild-type s-GDH (the mature protein) is given in Figure: 1 and SEQ ID NO: 24. Other LMD strains of *Acinetobacter* may also be used as source of wild-type s-GDH. Such sequences can be aligned to the sequence obtained from *A. calcoaceticus* and sequence comparisons be made (see Figure: 2). It also appears feasible to screen DNA-libraries of other bacterial

25 strains, as for example described for *E.coli* K-12 (Oubrie, A., et al., J Mol Biol 289 (1999) 319-33) above and to identify sequences related to s-GDH in such genomes. Such sequences and yet unidentified homologous sequences may be used to generate s-GDH mutants with improved substrate specificity for glucose.

The term "mutant" or "variant" in the sense of the present invention relates to a s-GDH

30 protein which compared to a corresponding wild-type sequence exhibits at least one amino acid substitution. The expert in the field will appreciate that there are various possibilities

to produce polynucleotides encoding for a polypeptide sequence of such mutated s-GDH. It is of course also possible to generate mutants comprising one or more additions or deletions of amino acids.

5   A mutant according to the present invention is characterized in that relative to the corresponding wild-type enzyme it has at least a two-fold improved substrate specificity for glucose as compared to at least one other selected sugar substrate.

In order to calculate the substrate specificity or cross-reactivity one easy way is to set the activity measured with glucose as substrate to 100% and to compare the activity measured with the other selected sugar to the glucose value. Sometimes, in order not to be redundant, 10   simply the term specificity is used without making special reference to glucose on the one hand and a selected other sugar substrate on the other hand.

The expert in the field will appreciate that comparison of (re-)activities is best made at equimolar concentrations of the substrate molecules investigated using well-defined assay conditions. Otherwise corrections for differences in concentrations have to be made.

15   Standardized and well-defined assay conditions have to be chosen in order to assess (improvements in) specificity. The enzymatic activity of s-GDH for glucose as substrate as well as for other selected sugar substrates is measured as described in Example 6.

Based on these measurements cross-reactivity and (improvements in) specificity are assessed.

20   The s-GDH (cross-)reactivity for a selected sugar in percent is calculated as

Cross-reactivity [%] = (activity selected sugar/activity glucose) x 100%.

(Cross-)reactivity for maltose of wild-type s-GDH according to the above formula has been determined as about 105%. Wild-type s-GDH (cross-)reactivity for galactose has been measured as about 50% (cf. Table 1).

25   (Improved) specificity is calculated according to the following formula:

$$\text{specificity (improvement)} = \frac{\text{activity glucose mutant}}{\text{activity glucose wild-type}} \times \frac{\text{activity selected sugar wild-type}}{\text{activity selected sugar mutant}}$$

As compared to the wild-type enzyme, a s-GDH form with an at least two-fold improvement in specificity for glucose versus maltose (maltose/glucose) accordingly with maltose as substrate has at most 52,5% of the activity as measured with glucose as substrate. Or, if, for example, a mutant s-GDH has a cross-reactivity for maltose of 20 % (determined and calculated as described above), this mutant as compared to the wild-type s-GDH therefore has a 5.25 fold improved substrate specificity (maltose/glucose).

The term "specific activity" for a substrate is well known in the art, it is preferably used to describe the enzymatic activity per amount of protein. Various methods are known to the art to determine specific activity of GDH molecules, using glucose or other sugars as substrates (Igarashi, S., et al., Biochem Biophys Res Commun 264 (1999) 820). One of the methods available for such measurement is described in detail in the examples section.

Whereas it is possible, to select many different sugar molecules and to investigate the glucose specificity of s-GDH in comparison to any such selected sugar molecule, it is preferred to select a clinically relevant sugar molecule for such a comparison. Preferred selected sugars are selected from the group consisting of mannose, allose, galactose, xylose, and maltose. More preferably, maltose or galactose are selected and mutant s-GDH is tested for improved substrate specificity for glucose as compared to galactose or maltose. In a further preferred embodiment the selected sugar is maltose.

It has surprisingly been found that the improvements in glucose specificity of mutated s-GDH, e.g., for maltose vs. glucose, are quite considerable. It is therefore further preferred that said substrate specificity for glucose as compared to the substrate specificity for at least one of the selected other sugar substrates is improved at least three-fold. Other preferred embodiments comprise s-GDH mutants characterized by an improved substrate specificity for glucose, which is at least 5 times higher or also preferred at least 10 times higher, as compared to the other sugar molecule selected.

Mutations in s-GDH lead in many cases to enzyme variants with drastically reduced specific activity for the substrate glucose. Such decrease in (absolute or overall) specific activity for the substrate glucose, however, may be critical for routine applications. Surprisingly it has been found that improved specificity for glucose must not go to the expense of a dramatically reduced overall specific activity. It is therefore preferred that the s-GDH with improved specificity towards the substrate glucose exhibits at least 10% of the specific activity for glucose as measured with the wild-type enzyme. It is of course more preferred that such mutated enzymes exhibit at least 20% or more preferred at least 50% of the respective glucose activity of wild-type s-GDH.

In a further preferred embodiment, the invention relates to a mutant of the soluble form of EC1.1.99.17 also known as PQQ-dependent soluble glucose dehydrogenase (s-GDH), said mutant characterized in that

a) the substrate specific reactivity towards glucose is essentially equal to that of the wild-type enzyme and

b) the substrate specific reactivity towards maltose is 30% or less as compared to the wild-type enzyme.

The substrate specific reactivity (also termed specific activity) towards glucose is considered to be essentially equal to that of the wild-type enzyme if at least 50% of the original enzymatic activity for glucose of the wild-type enzyme is maintained. Also preferred are mutants exhibiting at least 80 % or more preferred, at least 90 % of the specific activity for glucose as measured for the wild-type enzyme.

Quite surprisingly it has been found, that it is possible to obtain such s-GDH mutants or variants, which compared to the wild-type s-GDH exhibit essentially equal enzymatic activity for glucose but, nonetheless, significantly reduced substrate specific reactivity towards other selected sugars, especially towards maltose. Mutants characterized in that the substrate specific reactivity towards glucose is essentially equal to that of the wild-type enzyme and in that the substrate specific reactivity towards maltose is 20% or less as compared to the wild-type enzyme are preferred. Further preferred are such mutants for which the maltose specific activity is 15 % or even only 10% or less of the maltose specific activity as measured for the corresponding wild-type enzyme, whereas the specific

reactivity for glucose is essentially equal to the specific activity for glucose of the corresponding wild-type enzyme.

In case the wild-type enzyme is not well-characterized it is preferred to use the s-GDH from *Acinetobacter calcoaceticus*-type strain LMD 79.41 as reference. In a further preferred

5   embodiment the properties of an improved variant of s-GDH are compared to this wild-type enzyme and the present invention therefore relates to a mutant of s-GDH said mutant characterized in that relative to the wild-type enzyme of SEQ ID NO: 24 it exhibits essentially equal enzymatic activity for glucose but, significantly reduced (at least 70% less) substrate specific reactivity towards at least one other selected sugar substrate.

10   Unexpectedly it has been found that it is possible to generate s-GDH mutants with improved substitute specificity and even more unexpectedly it has been found that it is only a few well-defined amino acid positions which are of major relevance in that respect.

The achievements of the present invention are described in great detail by making reference to amino acid positions known from SEQ ID NO: 24, the wild-type sequence of s-GDH as

15   isolated from *Acinetobacter calcoaceticus*-type strain LMD 79.41. Amino acid positions in different s-GDH isolates corresponding to positions of SEQ ID NO: 24 are easily identified by appropriate sequence comparison. Preferably the PileUp program is used to assess homology or identity between such sequences. The amino acid positions given herein below shall be understood as amino acid positions of SEQ ID NO: 24 or of positions

20   corresponding thereto in other s-GDH molecules, unless specific reference is made to a different SEQ ID NO or to a different s-GDH isolate. In order to avoid redundances only in a few cases a specific hind to the fact that corresponding positions in different isolates can be modified in the same way is given, whereas for convenience in most cases simply and only the corresponding position from SEQ ID NO: 24 is used.

25   Mutants comprising an amino acid substitution at the position corresponding to position 348 of s-GDH have been found to exhibit a striking effect on specificity for glucose. As demonstrated in table 1, a variety of s-GDH variants with improved specificity for glucose can be identified and generated, as long as at least the amino acid in position threonine 348 – as corresponding to wild-type s-GDH sequence position from *A. calcoaceticus* – is

30   substituted with an appropriate other amino acid.

A preferred embodiment of the present invention therefore relates to a mutant protein of PQQ-dependent s-GDH comprising an amino acid residue substitution at the amino acid position corresponding to position 348 of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 24).

5   It has also been found, that combined substitutions of amino acids at amino acid positions corresponding to positions 348 and 428 of SEQ ID NO: 24 are advantageous to generate s-GDH mutants or variants with significantly improved specificity for glucose.

Residues 348 or 428 of s-GDH as isolated from *Acinetobacter calcoaceticus*-type strain LMD 79.41 are not known from the art to contribute to the substrate binding of s-GDH (Oubrie, A., et al., Embo J 18 (1999) 5187-94, ; Oubrie, A. and Dijkstra, B. W., Protein Sci 9 (2000)
10   1265-73). No chemical or physical explanation is at hand, why substitutions of these amino acid residues alters the substrate specificity of s-GDH for glucose as compared to other sugar molecules of interest.

It has been found in addition that substitution of amino acid 76 also has a positive effect on
15   glucose specificity of s-GDH.

In a further preferred embodiment the mutated s-GDH is characterized in that the amino acid residue threonine at position 348 is substituted with an amino acid residue selected from the group consisting of alanine, glycine, and serine. In a most preferred embodiment glycine is used to substitute for threonine at position 348.

20   One group of preferred s-GDH variants according to this invention comprises a substitution of the amino acid residue at position 348 and at at least one of the following positions 76, 143, 168, 169 and 428.

In yet a further embodiment a mutant protein of PQQ-dependent s-GDH comprises an amino acid residue substitution at position 428 of the correspondent wild-type sequence
25   from *Acinetobacter calcoaceticus*, in which the asparagine residue of the wild-type sequence is replaced by other appropriate amino acid residues. Preferably, such amino acid residue is selected from the group consisting of leucine, proline and valine. It is preferred to substitute the asparagine at position 428 with proline .

- 13 -

It further has proved that the amino acid glutamine at position 76 can be substituted to improve on the problems imposed by s-GDH cross-reactivity with other sugar molecules. Sequence positions of other s-GDH isolates corresponding to this sequence position are easily identified by a homology search based on SEQ ID NO:3. In another preferred
5 embodiment the mutant according to the present invention therefore comprises a substitution of glutamine at position 76 of the corresponding wild-type sequence from *Acinetobacter calcoaceticus*.

It is preferred to select the amino acid used in such substitution at a position corresponding to position 76 in SEQ ID NO: 24 from the group consisting of alanine, aspartic acid,
10 glutamic acid, glycine, methionine, proline and serine.

As described above, a substitution of the amino acid in position 348 of the s-GDH sequence corresponding to the wild-type sequence isolated from *A. calcoaceticus*, can be used to significantly improve the glucose specificity of s-GDH. Further improved mutants are obtained by providing a mutant s-GDH protein comprising at least two amino acid
15 substitutions, wherein the amino acid corresponding to amino acid position 348 of SEQ ID NO : 24 is substituted.

A further embodiment of the present invention therefore is a mutant s-GDH comprising at least two amino acid residue substitutions at an amino acid position corresponding to a position of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 24),
20 said substituted amino acid positions being selected from the group consisting of positions 16, 22, 76, 116, 120 ,127, 143, 168, 169, 171, 177, 227, 230, 231, 245, 255, 277, 295, 299, 308, 317, 341, 348, 349, 355, 422, 428 and 438, wherein the amino acid residue T348 is replaced. It is further preferred, that a s-GDH variant with the at least two substituted amino acid residues comprises a substitution in position 348 and at least one additional substitution
25 selected from the group of positions comprising positions 76, 143, 168, 169, and 428.

In a further preferred embodiment the at least two amino acid positions which are substituted in a mutant s-GDH are selected from the group consisting of amino acid positions 76, 348, and/or 428.

Mutants comprising substitutions at amino acid residues corresponding to positions 348
30 and 428 have been found as very advantageous for improving the specificity of s-GDH for

glucose in comparison to other sugar substrates. It is especially preferred to design and select mutants of s-GDH, which comprise a substitution at both the positions 348 and 428. Most preferred are mutants comprising the preferred substitutions as described above at both these positions. A s-GDH variant comprising T348G and N428P is most preferred.

5   The terminology T348G and N428P is known to the art to indicate that threonine at position 348 is replaced by glycine and glutamine and position 428 is replaced by proline.

Mutant s-GDH proteins comprising in addition to substitutions at positions 348 and 428 also substitutions at positions 76, 127 and 143, also represent preferred embodiments of the present invention.

10   Further preferred examples of mutated s-GDH proteins according to the present invention comprise amino acid substitutions at positions 76 and 348 and also such mutants comprising substitutions at positions 76 and 428. In yet another preferred embodiment the mutated s-GDH protein according to the present invention comprises substitutions of the amino acid residues at positions 76, 348 and 428.

15   In yet a further preferred embodiment the s-GDH variant according to the present invention comprises at least three amino acid substitutions, the at least three substituted amino acid residues corresponding to amino acid positions of the s-GDH wild-type sequence known from A. calcoaceticus (SEQ ID NO: 24), said substituted amino acid positions being selected from the group consisting of positions 171, 227, 230, 245, 341, 348,
20   349, and 428, wherein both the amino acid residues T348 and N428 are substituted. Preferably such trible mutants comprise at least one of the following substitutions: Y171G, H227F, P230H, E245D or M341V.

Preferred s-GDH variants with highly improved specificity for glucose comprise substitutions at positions 348 and 428 in combination with substitutions at positions 245
25   or 341, or both.

Amino acid sequence analysis revealed that the sequence motives found in wild-type s-GDH from A. calcoaceticus on the one hand and A. baumannii on the other hand appear to be very conservative around the positions of major relevance to improve the specificity for

- 15 -

glucose as identified in the present invention, i.e. positions 76, 348, and 428, as corresponding to wild-type s-GDH from *A. calcoaceticus* (c.f., Figure 2).

A preferred embodiment according to the present invention therefore is a mutant protein of PQQ-dependent s-GDH comprising the amino acid sequence of WPXaaVAPS (SEQ ID
5   NO: 1), wherein said Xaa residue is an amino acid residue other than threonine. SEQ ID NO:1 corresponds to position 346-352 of *A. calcoaceticus* wild-type s-GDH or position 347-353 of *A. baumannii* wild-type s-GDH.

Further preferred is an s-GDH mutant wherein said Xaa in SEQ ID NO: 1 represents alanine, glycine or serine, most preferred, Xaa represents glycine.

10   A mutant of PQQ-dependent s-GDH, comprising the amino acid sequence of TAGXaaVQK (SEQ ID NO: 2), wherein said Xaa residue is an amino acid residue other than asparagine, is another preferred embodiment of the invention. SEQ ID NO:2 corresponds to position 425-431 of *A. calcoaceticus* wild-type s-GDH or to position 426-432 of *A. baumannii* wild-type s-GDH.

15   Preferably the s-GDH mutant comprising SEQ ID NO:2 is characterized in that said Xaa residue is selected from the group consisting of leucine, proline and valine, most preferred Xaa is a proline residue.

Numerous possibilities are known in the art to produce mutant proteins. Based on the important findings of the present invention disclosing the critical importance of amino
20   acid positions 348 and 428 and also the utility of position 76, the skilled artisan now can easily produce further appropriate variants of s-GDH. Such variants for example can be obtained by the methods known as random mutagenesis (Leung, D. W., et al., Technique 1 (1989) 11-15) and/or directed mutagenesis (Hill, D. E., et al., Methods Enzymol 155 (1987) 558-68). An alternative method to produce a protein with the desired properties is to
25   provide chimaeric constructs, which contain sequence elements from at least two different sources or to completely synthesize an appropriate s-GDH gene. Such procedures known in the art may be used in combination with the information disclosed in the present invention to provide mutants or variants of s-GDH comprising at least one amino acid substitution at a sequence position corresponding to positions 348, and/or 428 of SEQ ID NO: 24.

A s-GDH variant according to the present invention can e.g., be produced by starting from a s-GDH gene as isolated from *Acinetobacter calcoaceticus*-type strain LMD 79.41 as well as by starting from a homologous sequence. In the context of this application the term "homologous" is meant to comprise wild-type s-GDH as isolated from other

5   microorganisms, provided that the sequence homology as compared to SEQ ID NO: 24 is at least 90 %. With other words, after appropriate alignment using the PileUp program, at least 90 % of the amino acids of that s-GDH are identical to the amino acids described in SEQ ID NO: 24.

It will be understood that variations of DNA and amino acid sequences naturally exist, or

10   may be intentionally introduced using methods known in the art. These variations may result in up to 10 % amino acid differences in the overall sequence, due to deletions, substitutions, insertions, inversions or additions of one or more amino acid residues in said sequence as compared to SEQ ID NO: 24. Such amino acid substitutions may be made, for example, on the basis of similarity in polarity, charge, solubility, hydrophobicity,

15   hydrophilicity and/or the amphipathic nature of the residues involved. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; amino acids with uncharged polar head groups or nonpolar head groups having similar hydrophilicity values include the following: leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine,

20   tyrosine. Other contemplated variations include salts and esters of the afore mentioned polypeptides, as well as precursors of the aforementioned polypeptides, for example, precursors having N-terminal substitution such as methionine, N-formylmethionine used as leader sequences. Such variations may be made without necessarily departing from the scope and the spirit of the present invention.

25   According to procedures known in the state of the art or according to the procedures given in the examples section, it is possible to obtain polynucleotide sequences coding for any of the s-GDH mutants as discussed above. The invention therefore comprises also isolated polynucleotide sequences encoding s-GDH mutant proteins as described above.

The present invention further includes an expression vector comprising a nucleic acid

30   sequence according to the present invention operably linked a promoter sequence capable of directing its expression in a host cell.

- 17 -

The present invention further includes an expression vector comprising a nucleic acid sequence according to the present invention operably linked to a promoter sequence capable of directing its expression in a host cell. Preferred vectors are plasmids such as pACSGDH shown in Figures 3 and 4.

5   Expression vectors useful in the present invention typically contain an origin of replication, a promoter located upstream in the DNA sequence and are followed by the DNA sequence coding for all or part of s-GDH variants. The DNA sequence coding for all or part of the s-GDH variants is followed by transcription termination sequences and the remaining vector. The expression vectors may also include other DNA sequences known in the art, for
10   example, stability leader sequences which provide for stability of the expression product, secretory leader sequences which provide for secretion of the expression product, sequences which allow expression of the structural gene to be modulated (e.g., by the presence or absence of nutrients or other inducers in the growth medium), marking sequences which are capable of providing phenotypic selection in transformed host cells, and the sequences
15   which provide sites for cleavage by restriction endonucleases.

The characteristics of the actual expression vector used must be compatible with the host cell, which is to be employed. For example, when cloning in an E.coli cell system, the expression vector should contain promoters isolated from the genome of E.coli cells (e.g., , lac, or trp). Suitable origins of replication in E.coli various hosts include, for example, a
20   ColE1 plasmid replication origin. Suitable promoters include, for example, lac and trp. It is also preferred that the expression vector includes a sequence coding for a selectable marker. The selectable marker is preferably an antibiotic resistance gene. As selectable markers, ampicillin resistance, or canamycin resistance may be conveniently employed. All of these materials are known in the art and are commercially available.

25   Suitable expression vectors containing the desired coding and control sequences may be constructed using standard recombinant DNA techniques known in the art, many of which are described in Sambrook et al. (1989).

The present invention additionally concerns host cells containing an expression vector which comprises a DNA sequence coding for all or part of the mutant s-GDH. The host
30   cells preferably contain an expression vector that comprises all or part of one of the DNA sequences having one or more mutations shown in Table 1. Further preferred are the host

cells containing an expression vector comprising one or more regulatory DNA sequences capable of directing the replication and/or the expression of, and operatively linked to a DNA sequence coding for, all or part of mutant s-GDH. Suitable host cells include, for example, *E.coli* HB101 (ATCC 33694) available from Pomega (2800 Woods Hollow Road,

5   Madison, WI, USA), XL1-Blue MRF available from Stratagene (11011 North Torrey Pine Road, La Jolla, CA, USA) and the like.

Expression vectors may be introduced into host cells by various methods known in the art. For example, transformation of host cells with expression vectors can be carried out by polyethylene glycol mediated protoplast transformation method (Sambrook et al. 1989).

10   However, other methods for introducing expression vectors into host cells, for example, electroporation, biolistic injection, or protoplast fusion, can also be employed.

Once an expression vector containing an s-GDH variant has been introduced into an appropriate host cell, the host cell may be cultured under conditions permitting expression of the desired s-GDH variants. Host cells containing an expression vector which contains a

15   DNA sequence coding for all or part of the mutant s-GDH are, e.g., identified by one or more of the following general approaches: DNA hybridization, the presence or absence of marker gene functions, assessment of the level of transcription as measured by the production of s-GDH mRNA transcripts in the host cell, and detection of the gene product immunologically. Preferably transformed host cells are identified by enzyme assay, e.g.,

20   colourimetric detection.

The present invention also teaches the generation and screening of s-GDH variants. Random mutagenesis and saturation mutagenesis is performed as known in the art. Variants are analyzed for substrate specificity for glucose, maltose as well as other sugars. The assay conditions chosen are adapted to ensure that the expected small enhancements

25   brought about e.g., by a single amino acid substitution, can be measured. This has been accomplished by adjusting the assay conditions such that the wild type (or parent) enzyme activity is close to the lower detection limit. One mode of selection or screening of appropriate mutants is given in Example 3. Any change or improvement as compared over the wild-type enzyme this way can be clearly detected.

30   It should, of course, be understood that not all expression vectors and DNA regulatory sequences would function equally well to express the DNA sequences of the present

invention. Neither will all host cells function equally well with the same expression system. However, one of ordinary skill in the art may make a selection among expression vectors, DNA regulatory sequences, and host cells using the guidance provided herein without undue experimentation and without departing from the scope of the present invention.

5   The invention also relates to a process for producing s-GDH variants of the current invention comprising culturing a host cell of the invention under conditions suitable for production of the mutant s-GDH of the invention. For bacterial host cells, typical culture conditions are liquid medium containing the appropriate antibiotic and induction agent. Typical appropriate antibiotics include ampicillin, canamycin, chloroamphenicol, 10   tetracyclin and the like. Typical induction agents include IPTG, glucose, lactose and the like.

It is preferred that the polypeptides of the present invention are obtained by production in host cells expressing a DNA sequence coding the mutant s-GDH. The polypeptides of the present invention may also be obtained by *in vitro* translation of the mRNA encoded by a 15   DNA sequence coding for the mutant s-GDH. For example, the DNA sequences may be synthesized as described above and inserted into a suitable expression vector, which in turn may be used in an *in vitro* transcription/translation system.

An expression vector comprising an isolated polynucleotide as defined and described above operably linked to a promoter sequence capable of promoting its expression in a cell-free 20   peptide synthesis system represents another preferred embodiment of the present invention.

The polypeptides produced e.g. by procedures as describe above, may then be isolated and purified using various routine protein purification techniques. For example, chromatographic procedures such as ion exchange chromatography, gel filtration 25   chromatography and affinity chromatography may be employed.

One of the major applications of the improved s-GDH variants of this invention is for the use in test strips to monitor blood-glucose level in diabetic patients. Due to the insensitivity of PQQ-dependent glucose dehydrogenase towards oxygen, a system using the improved s-GDH variants is less prone to interference by oxygen than systems based on glucose 30   oxidase. More important, since the s-GDH variants have improved specificity towards

glucose and significantly decreased relative enzymatic activity towards other sugars, the interference due maltose, galactose, and/or other related sugars which may be present in a sample to be analyzed is significantly reduced. Of course many kinds of samples may be investigated. Bodily fluids like serum, plasma, intestinal fluid or urine are preferred sources
5   for such samples.

The invention also comprises a method of detecting, determining or measuring glucose in a sample using a s-GDH mutant according to the present invention. It is especially preferred that the improved method for detection of glucose in a sample is characterized in that said detection, determination or measurement of glucose is performed using a sensor or test
10   strip device.

Also within the scope of the present invention is a device for the detection or measurement of glucose in a sample comprising a s-GDH mutant according to this invention as well as other reagents required for said measurement.

The s-GDH variants with improved substrate specificity of this invention can also be used
15   to great advantage in biosensors (D'Costa, E. J., et al., Biosensors 2 (1986) 71-87; Laurinavicius, V., et al., Analytical Letters 32 (1999) 299-316; Laurinavicius, V., et al., Monatshefte fuer Chemie 130 (1999) 1269-1281) for online monitoring of glucose in a sample or a reactor. For this purpose, the s-GDH variants can, for example, be used to coat an oxygen-insensitive glassy electrode with an osmium complex containing a redox
20   conductive epoxy network (Ye et al., 1993, supra) for more accurate determination of the glucose concentration.

There are also other possible applications of the s-GDH variants with the improved substrate specificity according to this invention. For example, these s-GDH variants may be used in an aldonic acid production process. Wild-type s-GDH has a high turnover in
25   substrate oxidation producing gluconic and other aldonic acids. By using the s-GDH variants, which are more specific for glucose, the production of gluconic acid would result in much less byproducts. With other s-GDH variants of different substrate specificity, it is possible to produce different aldonic acids as required.

In the following examples, all reagents, restriction enzymes, and other materials were
30   obtained from Roche Diagnostics Germany, unless other commercial sources are specified,

and used according to the instructions given by the suppliers. Operations and methods employed for the purification, characterization and cloning of DNA are well known in the art (Ausubel, F., et al., in "Current protocols in molecular biology" (1994), Wiley Verlag) and can be adapted as required by the skilled artisan.

5   The following examples further illustrate the present invention. These examples are not intended to limit the scope of the present invention, but provide further understanding of the invention.

Example 1

10   Cloning and expression of the wild-type *A. calcoaceticus* soluble PQQ dependent glucose dehydrogenase in *E. coli*

The s-GDH gene was isolated from *Acinetobacter calcoaceticus* strain LMD 79.41 according to standard procedures. The wild-type s-GDH gene was subcloned into a plasmid containing the mgl promoter for adjustabel expression (cf. Patent application WO 15   88/09373). The new construct was called pACSGDH (see Figures 3 and 4). The recombinant plasmids was introduced into a host organism selected from the *E.coli* group. These organisms were then cultivated under appropriate conditions and colonies showing s-GDH activity selected.

The plasmid pACSGDH was isolated from a 200 ml over-night culture of the clone 20   mentioned above using the QIAGEN Plasmid Maxi Kit (Qiagen) according to the manufacturers protocol. The plasmid was resuspended in 1 ml bidest. water. The concentration of the plasmid was determined using a Beckman DU 7400 Photometer. The yield was 600 µg. Then the quality of the plasmid was determined by agarose gel electrophoresis.

25   Example 2:

Mutagenic PCR

To generate random mutations in the s-GDH-gene, mutagenic PCR (polymerase chain reaction) was performed. The pACSGDH plasmid and the DNA sequence encoding the 30   mutated enzymes (PCR product from mutagenic PCR) were digested with the restriction

- 22 -

enzymes *Sph* I and *Eco* RI. The products were gel purified. The digested DNA sequences were ligated and an aliquot of the ligation reaction mixture was used to transform competent *E.coli* cells. The transformants were subsequently selected on LB plates containing ampicillin.

5 To assay, individual colonies were chosen, grown over night in LB medium containing ampicillin and subjected to screening (see Example 3) .

Mutagenic PCR reaction mixture:

40 ng pACSGDH

1 x buffer without MgCl2 (Roche Diagnostics GmbH, Cat. 1699 105)

10 dCTP, dTTP 1mM

dATP, dGTP 0.2 mM (Roche Diagnostics GmbH, Cat. 1969 064)

40 pmol GF23-Primer (5'-CGC GCA CGC GCA TGC CGC CGA TGT TC) (= SEQ ID NO: 4)

40 pmol GR23 (5'-GAC GGC CAG TGA ATT CTT TTC TA) (= SEQ ID NO: 5)

15 7 mM MgCl2

0.6 mM MnCl2

5 U Taq DNA polymerase (Roche Diagnostics GmbH, Cat. 1146 165)

Gene Amp PCR System 2400 (Perkin Elmer), 30 cycles: 95 °C 1 min, 45 °C 2 min, 72 °C 2 min

20 - Purification of the PCR products using the High Pure PCR Product Purification Kit from Roche Diagnostics GmbH (Cat. 1 732 676) according to the manufacturers protocol.

- Digestion of the PCR-fragments with 25 U *SphI* (Roche Diagnostics GmbH, Cat. 606 120) in 1 x buffer H (Roche Diagnostics GmbH, Cat. 1 417 991) at 37 °C over night;

- 23 -

addition of 25 U *EcoRI* (Roche Diagnostics GmbH, Cat. 703 737) and further digestion for 3.5 hours

- Digestion of 50 µg pACSGDH with 180 U *SphI* and 180 U *EcoRI* in 1 x buffer H for 4 hours at 37 °C.

5 - Gel electrophoresis of the digested pACSGDH and the digested fragments using agarose gels (0.8 %)

- Extraction of the DNA molecules using QIAquick Gel Extraction Kit (Qiagen, Cat. 28706) according to the manufacturers protocol

- Determination of the concentration of the fragments and the digested vector using a
10 Beckman DU 7400 Photometer

- Determination of the quality of the purified products by agarose gel electrophoresis

- Ligation of 100 ng digested vector with 140 ng mPCR-fragments using 1 U T4-DNA-Ligase (Roche Diagnostics GmbH, Cat. 481 220) in a volume of 20 µl at 16 °C over night

15 - Electroporation of electrocompetent XL1F- cells (Stratagene) with 1 µl of the ligation reaction with 2.5 KV in 0.2 cm cuvettes using a BioRad *E. coli* Pulser (BioRad)

- After growth in 1 ml LB at 37 °C for one hour, bacteria were plated on LB-Ampicillin Agar plates (100 µg / ml Ampicillin) and grown over night at 37 °C.

- 50 % of these clones expressing mutated s-GDH were active using the following
20 screening method.

- 24 -

Example 3:

Screening

The mutant colonies on agar plates described above where picked in microtiter plates
5   (mtp) containing 200 µl LB-Ampicillin-media/well and incubated over night at 37 °C.
These plates are called master plates.

From each master plate, 5 µl sample/well was transferred to a mtp containing 5 µl per/well
of B (B=Bacterial Protein Extraction Reagent; Pierce No. 78248) for cell disruption and
240 µl of 0.0556 mM pyrollo-quinoline quinone(PQQ); 50 mM Hepes; 15 mM CaCl2 pH
10   7.0/well for activation of s-GDH were added. To complete the formation of the
holoenzyme, the mtp was incubated at 25°C for 2 hours and at 10 °C over night. This plate
is called working plate.

From the working plate 2 x 10 µl sample/hole were transferred to two empty mtps. After
that, one was tested with glucose and the other with maltose or other selected sugar
15   molecules as a substrate. All sugar molecules were used in equimolar concentrations.

The dE/min was calculated and the value using glucose as substrate was set to 100%
activity. The value obtained with the other sugar was compared to the glucose value and
calculated in percent activity ((dE/min Maltose/dE Glucose)*100). This is equivalent to the
cross-reactivity of the (mutant) enzyme.

20   Example 4:

Sequencing of mutant s-GDH gene from mutagenic PCR

The plasmid containing the mutant s-GDH gene that leads to 50 % maltose/glucose activity
was isolated (High Pure Plasmid Isolation Kit, Roche Diagnostics GmbH, No. 1754785)
25   and sequenced using an ABI Prism Dye Terminator Sequencing Kit and ABI 3/73 and 3/77
sequencer (Amersham Pharmacia Biotech).

Following primers were used:

- 25 -

Sense strand: GDH F2 : 5´-TTA ACG TGC TGA ACA GCC GG-3´ (= SEQ ID NO: 6)

GDH F3: 5´-GAT GCT GAT GGG CAG AAT GG-3´ (= SEQ ID NO: 7)

GDH F4: 5´-ATA TGG GTA AAG TAC TAC GC -3´ (= SEQ ID NO: 8)

GDH F5: 5´-ACG ATC CAA CTT GTG GAG AG-3´ (= SEQ ID NO: 9)

5   Antisense strand: GDH R1: 5´-CGA TTA AGT TGG GTA ACG CC-3´ (= SEQ ID NO: 10)

GDH R2: 5´-ATA CGG AAA ATG ACA CCA CG-3´ (= SEQ ID NO: 11)

GDH R3: 5´-GGG CCT TGT TCA GAC TGC AA-3´ (= SEQ ID NO: 12)

GDH R4: 5´-CAA GAC GAC CTG ACT GAT GG-3´ (= SEQ ID NO: 13)

GDH R5: 5´-CAT AAC AAC GCG TGC GGC TT-3´ (= SEQ ID NO: 14)

10   <u>Results:</u>

=>6 mutations on DNA sequence level

⇨ 4 mutations on amino acid level:

at position 340 (mature enzyme) change from E to G

15   at position 348 (mature enzyme) change from T to S

at position 369 (mature enzyme) change from N to H

at position 413 (mature enzyme) change from S to N

<u>Example 5:</u>

20   s-GDH mutants obtained by saturation mutagenesis

The QuickChange Site-Directed Mutagenesis Kit (Stratagene, Cat. 200518) was used to substitude successively wild type amino acids at defined positions of the s-GDH-protein or

of s-GDH-mutants (plasmide purification as discribed above) with other random amino acids.

The 5'- and the 3'-primer used for mutagenesis were complementary to each other and contained NNN in a central position. These nucleotides were flanked by 12 to 16
5   nucleotides at each end. The sequences of the nucleotides were identical to the cDNA-strand or to the complementary cDNA-strand flanking the codon for the amino acid that had to be substituted. Instead of the codon, the primer contained NNN therefore the oligonucleotides code for every codon.

For every defined position, one PCR reaction was performed.

10   The PCR-reactions and the *DpnI* digestions were performed according to the manual.

After that, 1 μl of each reaction was used for the electroporation of XL1F- cells. Cells were grown and the s-GDH activity of the clones was determined as described above.

To ensure statistically that all 20 amino acids variants were screened, 200 clones were tested for each position.

15   The following primers where used:

for position 340   Sense strand   EGF 5'-TCC AAC TTG TGG ANN N AT GAC CTA CAT TT-3' (= SEQ ID NO: 15)

Antisense strand   EGR 5'- AAA TGT AGG TCA TNN NTC CAC AAG TTG GA-3' (= SEQ ID NO: 16)

20   for position 348 Sense strand TSF 5'- CAT TTG CTG GCC ANN NGT TGC ACC GTC AT-3' (= SEQ ID NO: 17)

Antisense strand   TSR 5'- ATG ACG GTG CAA CNN NTG GCC AGC AAA TG-3' (= SEQ ID NO: 18)

for position 369 Sense strand NHF 5′-TAC TGG TTG GGA ANN NAC ATT ATT GGT TC -3′ (= SEQ ID NO: 19)

Antisense strand   NHR 5′- GAA CCA ATA ATG TNN NTT CCC AAC CAG TA-3′ (= SEQ ID NO: 20)

for position 413 Sense strand SNF 5′-TGA TGT GAT TGC ANN NCC AGA TGG GAA TG -3′ (= SEQ ID NO: 21)

Antisense strand   SNR 5′- CAT TCC CAT CTG GNN NTG CAA TCA CAT CA-3′ (= SEQ ID NO: 22)

<u>Results:</u>

The amino acid changes at positions 340, 369 and 413 didn't change the substrate specificity. Only the wobble at position 348 did yield clones with a substrate specificity from 25-100 % (maltose/glucose).

Numerous rounds of mutagenic PCR and saturation mutagenesis were performed. It was found and confirmed that positions 348 and 428 are of major importance and that exchange of other amino acids may further improve the specificity for glucose of mutated s-GDH. Representative data and positions are given in table 1.

<u>Table 1: Examples for s-GDH-variants with improved specificity for glucose</u>

Abbreviations: n.t.   = not tested

SA   = specific activity (U/mg protein) with glucose as substrate

Changed amino acid to wildtype sequence	Glucose conversion	Maltose conversion	Galactose conversion	SA
wild-type	100%	105%	50%	1000
340 E to G 348 T to S 369 N to H 413 S to N	100%	50%	25%	700
22 I to L	100%	123%	14%	178

295 Q to L 422 L to I				
348 T to D	100%	80%	n.t.	n.t.
348 T to A	100%	67%	n.t.	n.t.
348 T to G	100%	22%	20%	910
428 N to P 348 T to G	100%	8%	25%	n.t.
428 N to V 348 T to G	100%	22%	22%	n.t.
127 T to M 143 D to Q 348 T to G 428 N to P	100%	1%	32%	n.t.
76 Q to A 348 T to G	100%	17%	n.t.	n.t.
76 Q to M 348 T to G	100%	18%	n.t.	n.t.
76 Q to D 348 T to G	100%	17%	n.t.	n.t.
76 Q to P 348 T to G	100%	17%	n.t.	n.t.
76 Q to S 348 T to G	100%	17%	n.t.	n.t.
76 Q to G 348 T to G	100%	20%	n.t.	n.t.
76 Q to E 348 T to G	100%	17%	n.t.	n.t.
143 D to E 348 T to G	100%	17%	n.t.	n.t.
171 Y to H 348 T to G 308 K to N	100%	19%	n.t.	n.t.
171 Y to D 348 T to G 317 F to V	100%	18%	n.t.	n.t.
127 T to S 169 L to H 348 T to G 355 Y to H	100%	11%	n.t.	n.t.
16 N to D 120 T to S	100%	22%	n.t.	n.t.

177 Q to R 277 Y to H 348 T to G				
116 I to T 255 N to T 299 K to R 348 T to G	100%	20%	n.t.	n.t.
227 H to Y 348 T to G 438 N to S	100%	18%	n.t.	n.t.
341 M to V 348 T to G	100%	20%	n.t.	n.t.
348 T to G 349 V to G 428 N to P	100%	10%	n.t.	n.t.
171 Y to G 230 P to H 348 T to G 428 N to P	100%	3%	n.t.	n.t.
230 P to H 348 T to G 428 N to P	100%	10%	n.t.	200
227 H to F 230 P to H 348 T to G 428 N to P	100%	6%	n.t.	n.t.
143 D to E 348 T to G	100%	17%	n.t.	n.t.
143 D to E 348 T to G 428 N to P	100%	1%	32%	n.t.
169 G to X 230 P to H 348 T to G 428 N to P	100%	2%	n.t.	n.t.

- 30 -

Example 6:

Purification of mutant s-GDH T348G

The grown cells (LB-Amp. 37 °C) were harvested and resuspended in potassium phosphate
buffer pH 7.0. Cell disruption was performed by French Press passage (700-900 bar). After
centrifugation the supernatant was applied to a S-Sepharose (Amersham Pharmacia Biotec)
column equilibrated with 10 mM potassium phosphate buffer pH 7.0. After washing, the s-
GDH was eluted using a salt gradient 0-1 M NaCl. The fractions showing s-GDH activity
were pooled, dialysed against potassium phosphate buffer pH 7.0 and re-chromatographied
on re-equilibrated S-sepharose column. The active fractions were pooled and subjected to
a gel filtration using a Superdex® 200 column (Amersham Pharmacia Biotec). The active
fractions were pooled and stored at –20 °C.

Enzyme assay and Protein determination of mutant T348G and wildtype s-GDH
Protein determination was performed using the Protein Assay Reagent no. 23225 from
Pierce (calibration curve with BSA, 30 Min. 37 °C).

The GDH samples were diluted to 1 mg protein/ml with 0.0556 mM pyrollo-quinoline
quinone(PQQ); 50 mM Hepes; 15 mM $CaCl_2$ pH 7.0 and incubated at 25°C for 30 minutes
for reconstitution or activation.

After activation 50 µl of sample were added to 1000 µl of a 0.2 M citrate buffer solution (pH
5.8; at 25°C) containing 0.315 mg (4-(dimethylphosphinylmethyl)-2-methyl-pyrazolo-
[1.5a]-imidazol-3-yl)-(4-nitrosophenyl)-amine (see patent US 5,484,708)/ml as a mediator
and 33 mM sugar).

Extinction at 620 nm is monitored during the first 5 minutes at 25 °C.

One Unit enzyme activity corresponds the conversion of 1 mMol mediator/min under the
above assay conditions

Calculation: Activity = (total volume * dE/min [U/ml]) : (ε * sample volume * 1)

(ε = coefficient of extinction; in this example $\varepsilon_{620\,nm}$ = 30[1* $mmol^{-1}$ * cm^{-1}]).

The assay was performed with glucose, maltose and galactose (Merck, Germany).

Results:

Sample	Specific activity U/mgProtein (glucose as substrate)	% maltose/glucose conversion	% galactose/glucose conversion
wilde-type	1000	105%	50%
Mutant T348G	910	22%	20%

5   Example 7: Determination of glucose in the presence or absence of maltose

The wild-type and mutant T348G of s-GDH were applied for glucose determination. The reference samples contained 65 mg glucose/dl. The "test"-sample contained 65 mg glucose/dl and 130 mg/dl maltose. The same amounts of GDH activity (U/ml; see enzyme
10   assay) were used for each assay.

In a cuvette was mixed:

1 ml   0.315   mg   (4-(dimethylphosphinylmethyl)-2-methyl-pyrazolo-[1.5a]-imidazol-3-yl)-(4-nitrosophenyl)-amine ml/0.2 M citrate pH 5.8

0.015 ml sample (glucose or glucose + maltose)

15   The assay was started adding 0.050 ml 90 U/ml s-GDH . The change of absorption at 620 nm was monitored. After 5 minutes constant values were observed and the dE/5 min calculated. The value obtained measuring the reference sample with wild-type s-GDH was set to 100%. The other values were compared to this reference value and calculated in %.

Results:

20

	65 mg/dl glucose	65 mg/dl glucose and 130 mg/dl maltose
wild-type s-GDH	100%	190%
mutant s-GDH T348G	100%	130%

It can be clearly seen that the „glucose-value" measured is markedly less impaired when the mutated s-GDH is used in this determination.

- 32 -

List of References

Anthony C., 1996. Quinoprotein-catalysed reactions. Biochem. J. 320(3):697-711

Anthony C., Ghosh M., 1997. The structure and function of PQQ-containing quinoproteins. Curr. Sci. 72(10):716-727

5   Anthony, C., Biochem J 320 (1996) 697-711

Anthony, C. and Ghosh, M., Current Science 72 (1997) 716-727

Anthony, C. and Ghosh, M., Prog Biophys Mol Biol 69 (1998) 1-21

Anthony, C., Biochem Soc Trans 26 (1998) 413-7

Ausubel, F., et al., in "Current protocols in molcular biology" (1994), Wiley Verlag

10 Cleton-Jansen, A. M., et al., Antonie Van Leeuwenhoek 56 (1989) 73-9

Cleton-Jansen, A. M., et al., J Bacteriol 170 (1988) 2121-5

Cleton-Jansen, A. M., et al., Mol Gen Genet 217 (1989) 430-6

Davidson, V. L. in "Principles and applications of quinoproteins" (1993) the whole book, New York, Marcel Dekker

15 D'Costa, E. J., et al., Biosensors 2 (1986) 71-87

Dokter, P., et al., FEMS Microbiology Letters 43 (1987) 195-200

Dokter, P., et al., Biochem J 239 (1986) 163-7

Dokter, P., et al., Biochem J 254 (1988) 131-8

Duine, J. A. Energy generation and the glucose dehydrogenase pathway in *Acinetobacter* in

20   "The Biology of *Acinetobacter*" (1991) 295-312, New York, Plenum Press

Duine, J. A., Biosens. Bioelectronics 10 (1995) 17-23

Duine, J. A., et al., Arch Microbiol 131 (1982) 27-31

Duine, J. A., Eur J Biochem 200 (1991) 271-84

Goodwin, P. M. and Anthony, C., Adv Microb Physiol 40 (1998) 1-80

25 Hill, D. E., et al., Methods Enzymol 155 (1987) 558-68

Igarashi, S., et al., Biochem Biophys Res Commun 264 (1999) 820-4

Kaufmann, N., et al. Development and evaluation of a new system for determining glucose from fresh capillary blood and heparinised venous blood in "Glucotrend" (1997) 1-16, Mannheim, Boehringer Mannheim GmbH

30 Laurinavicius, V., et al., Analytical Letters 32 (1999) 299-316

Laurinavicius, V., et al., Monatshefte fuer Chemie 130 (1999) 1269-1281

Leung, D. W., et al., Technique 1 (1989) 11-15

Matsushita, K. and Adachi, O. Bacterial quinoproteins glucose dehydrogenase and alcohol dehydrogenase in "Principles and applications of Quinoproteins" (1993) 47-63,

35   New York, Marcel Dekker

Matsushita, K., et al., Antonie Van Leeuwenhoek 56 (1989) 63-72

Matsushita, K., et al., Biochemistry 28 (1989) 6276-80

Matsushita, K., et al., Bioscience Biotechnology & Biochemistry 59 (1995) 1548-1555

Oliphant, A. R., et al., Gene 44 (1986) 177-83

5   Olsthoorn, A. J. and Duine, J. A., Arch Biochem Biophys 336 (1996) 42-8

Olsthoorn, A. J. and Duine, J. A., Biochemistry 37 (1998) 13854-61

Oubrie, A. and Dijkstra, B. W., Protein Sci 9 (2000) 1265-73

Oubrie, A., et al., Embo J 18 (1999) 5187-94

Oubrie, A., et al., J Mol Biol 289 (1999) 319-33

10   Oubrie, A., et al., Proc Natl Acad Sci U S A 96 (1999) 11787-91

Sambrook, J., et al. - in "Molecular Cloning: A Laboratory Manual" (1989) -, Cold Spring
         Harbour, NY, Cold Spring Harbour Laboratory Press

Wens, R., et al., Perit Dial Int 18 (1998) 603-9

Ye, L., et al., Anal. Chem. 65 (1993) 238-41

15

EP 0 620 283

JP 11243949

US 5,484,708

US 5,997,817

20   US 6,057,120

US 6,103,509

WO 92/07953

WO 99/30152

WO 88/09373

- 34 -

Patent Claims

1. A mutant of the soluble form of EC 1.1.99.17 also known as PQQ-dependent soluble glucose dehydrogenase (s-GDH) said mutant characterized in that relative to the corresponding wild-type enzyme and with regard to at least one other selected sugar substrate, it has an at least two-fold increased substrate specificity for glucose.

2. The mutant according to claim 1 further characterized in that said selected sugar is selected from the group consisting of maltose and galactose.

3. The mutant according to claim 1 or 2 further characterized in that said selected sugar is maltose.

4. The mutant of PQQ-dependent s-GDH according to Claim 1 further characterized in that said substrate specificity for glucose is improved at least 3-fold.

5. The mutant of PQQ-dependent s-GDH according to Claim 1 further characterized in that said substrate specificity for glucose is improved at least 5-fold.

6. A mutant of the soluble form of EC 1.1.99.17 also known as PQQ-dependent soluble glucose dehydrogenase (s-GDH) said mutant characterized in that

   a) the substrate specific reactivity towards glucose is essentially equal to that of the wild-type enzyme, and

   b) the substrate specific reactivity towards maltose is 30% or less as compared to the wild-type enzyme.

7. The mutant according to claim 6 further characterized in that said substrate specific reactivity towards maltose is 20% or less as compared to the wild-type enzyme.

8. The mutant of a PQQ-dependent s-GDH according to any of claims 1- 7 further characterized in that the wild-type s-GDH is isolated from a strain of the *Acinetobacter* species group consisting of *A. calcoaceticus* and *A. baumannii*.

- 35 -

9. A mutant protein of PQQ-dependent s-GDH comprising an amino acid residue substitution at the amino acid position corresponding to position 348 of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 24).

10. A mutant protein of PQQ-dependent s-GDH comprising at least two amino acid residue substitutions at amino acid positions corresponding to positions of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 24), said substituted amino acid positions being selected from the group consisting of positions 16, 22, 76, 116, 120 ,127, 143, 168, 169, 171, 177, 227, 230, 231, 245, 255, 277, 295, 299, 308, 317, 341, 348, 349, 355, 422, 428 and 438, wherein the amino acid residue T348 is replaced.

11. The mutant of claim 10 further characterized in that at amino acid positions corresponding to positions of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 24) the amino acid in position 348 and at least one of the following amino acid residues 16, 116, 120, 127, 169, 171, 177, 227, 255, 277, 299, 317, 355 and 438 are substituted.

12. The mutant protein of claim 10 comprising substitutions of the amino acid residues at positions 348 and 428.

13. A mutant protein of PQQ-dependent s-GDH comprising at least three amino acid residue substitutions at amino acid positions corresponding positions of the s-GDH wild-type sequence known from *A. calcoaceticus* (SEQ ID NO: 24), said substituted amino acid positions being selected from the group consisting of positions 171, 227, 230, 245, 341, 348, 349, and 428 wherein both the amino acid residues T348 and N428 are substituted.

14. The mutant according to claim 12 or 13 further characterized in that asparagine at position 428 is substituted with an amino acid residue selected from the group consisting of leucine, proline and valine.

15. The mutant according to any of claims 9 to 14 further characterized in that threonine at position 348 is substituted with an amino acid residue selected from the group consisting of alanine, glycine and serine.

16. A mutant protein of PQQ-dependent s-GDH comprising the amino acid sequence of WPXaaVAPS (SEQ ID NO: 1), wherein said Xaa residue is an amino acid residue other than threonine.

17. The mutant protein of claim 16 further characterized in that said Xaa residue is glycine.

5   18. A mutant protein of PQQ-dependent s-GDH comprising the amino acid sequence of TAGXaaVQK (SEQ ID NO: 2), wherein said Xaa residue is an amino acid residue other than asparagine.

19. The mutant protein of claim 18 further characterized in that said Xaa residue is proline.

20. A mutant protein of PQQ-dependent s-GDH comprising the amino acid sequence of
10   ADGXaaNGL (SEQ ID NO: 3), wherein said Xaa residue is an amino acid residue other than glutamine.

21. The mutant of claim 20 further characterized in that said Xaa residue is selected from the group consisting of aspartic acid, glutamic acid, methionine, proline, serine, alanine or glycine.

15   22. An isolated polynucleotide encoding the s-GDH mutant protein according to any of claims 9 to 21.

23. An expression vector comprising an isolated polynucleotide as defined in claim 22 operably linked to a promoter sequence capable of promoting the expression of said polynucleotide in a host cell.

20   24. A host cell comprising the expression vector of claim 23.

25. A process for producing s-GDH variants comprising culturing the host cell of claim 24 under conditions suitable for production of the enzyme variants.

26. An expression vector comprising an isolated polynucleotide as defined in claim 22 operably linked to a promoter sequence capable of promoting its expression in a cell-
25   free peptide synthesis system.

27. A process for producing s-GDH variants with the construct of claim 26 in a cell-free peptide synthesis system under conditions suitable for production of the said enzyme variants.

28. A method of detecting, determining or measuring glucose in a sample using a s-GDH mutant according to any of the preceeding claims, said improvement comprising contacting the sample with the mutant.

29. The method of claim 28 further characterized in that said detection, determination or measurement of glucose is performed using a sensor or test strip device.

30. A device for the detection or measurement of glucose in a sample comprising a s-GDH mutant according to any of claims 1- 29 and other reagents required for said measurement.

●   ●

Figure 1: DNA and protein sequence of A. calcoaceticus s-GDH
-              (without signalpeptide)

```
5         1 GATGTTCCTCTAACTCCATCTCAATTTGCTAAAGCGAAATCAGAGAACTT 50
            ||||||||||||||||||||||||||||||||||||||||||||||||||
          1 AspValProLeuThrProSerGlnPheAlaLysAlaLysSerGluAsnPh 17

         51 TGACAAGAAAGTTATTCTATCTAATCTAAATAAGCCGCACGCGTTGTTAT 100
10          ||||||||||||||||||||||||||||||||||||||||||||||||||
         18 eAspLysLysValIleLeuSerAsnLeuAsnLysProHisAlaLeuLeuT 34

        101 GGGGACCAGATAATCAAATTTGGTTAACTGAGCGAGCAACAGGTAAGATT 150
            ||||||||||||||||||||||||||||||||||||||||||||||||||
15       35 rpGlyProAspAsnGlnIleTrpLeuThrGluArgAlaThrGlyLysIle 50

        151 CTAAGAGTTAATCCAGAGTCGGGTAGTGTAAAAACAGTTTTTCAGGTACC 200
            ||||||||||||||||||||||||||||||||||||||||||||||||||
         51 LeuArgValAsnProGluSerGlySerValLysThrValPheGlnValPr 67
20
        201 AGAGATTGTCAATGATGCTGATGGGCAGAATGGTTTATTAGGTTTTGCCT 250
            ||||||||||||||||||||||||||||||||||||||||||||||||||
         68 oGluIleValAsnAspAlaAspGlyGlnAsnGlyLeuLeuGlyPheAlaP 84

25      251 TCCATCCTGATTTTAAAAATAATCCTTATATCTATATTTCAGGTACATTT 300
            ||||||||||||||||||||||||||||||||||||||||||||||||||
         85 heHisProAspPheLysAsnAsnProTyrIleTyrIleSerGlyThrPhe 100

        301 AAAAATCCGAAATCTACAGATAAAGAATTACCGAACCAAACGATTATTCG 350
30          ||||||||||||||||||||||||||||||||||||||||||||||||||
        101 LysAsnProLysSerThrAspLysGluLeuProAsnGlnThrIleIleAr 117

        351 TCGTTATACCTATAATAAATCAACAGATACGCTCGAGAAGCCAGTCGATT 400
            ||||||||||||||||||||||||||||||||||||||||||||||||||
35      118 gArgTyrThrTyrAsnLysSerThrAspThrLeuGluLysProValAspL 134

        401 TATTAGCAGGATTACCTTCATCAAAAGACCATCAGTCAGGTCGTCTTGTC 450
            ||||||||||||||||||||||||||||||||||||||||||||||||||
        135 euLeuAlaGlyLeuProSerSerLysAspHisGlnSerGlyArgLeuVal 150
40
        451 ATTGGGCCAGATCAAAAGATTTATTATACGATTGGTGACCAAGGGCGTAA 500
            ||||||||||||||||||||||||||||||||||||||||||||||||||
        151 IleGlyProAspGlnLysIleTyrTyrThrIleGlyAspGlnGlyArgAs 167

45      501 CCAGCTTGCTTATTTGTTCTTGCCAAATCAAGCACAACATACGCCAACTC 550
            ||||||||||||||||||||||||||||||||||||||||||||||||||
        168 nGlnLeuAlaTyrLeuPheLeuProAsnGlnAlaGlnHisThrProThrG 184

        551 AACAAGAACTGAATGGTAAAGACTATCACACCTATATGGGTAAAGTACTA 600
50          ||||||||||||||||||||||||||||||||||||||||||||||||||
        185 lnGlnGluLeuAsnGlyLysAspTyrHisThrTyrMetGlyLysValLeu 200

        601 CGCTTAAATCTTGATGGAAGTATTCCAAAGGATAATCCAAGTTTTAACGG 650
            ||||||||||||||||||||||||||||||||||||||||||||||||||
55      201 ArgLeuAsnLeuAspGlySerIleProLysAspAsnProSerPheAsnGl 217

        651 GGTGGTTAGCCATATTTATACACTTGGACATCGTAATCCGCAGGGCTTAG 700
            ||||||||||||||||||||||||||||||||||||||||||||||||||
        218 yValValSerHisIleTyrThrLeuGlyHisArgAsnProGlnGlyLeuA 234
60
        701 CATTCACTCCAAATGGTAAATTATTGCAGTCTGAACAAGGCCCAAACTCT 750
            ||||||||||||||||||||||||||||||||||||||||||||||||||
        235 laPheThrProAsnGlyLysLeuLeuGlnSerGluGlnGlyProAsnSer 250
```

Figure 1: Continued (second and last page)

```
  751 GACGATGAAATTAACCTCATTGTCAAAGGTGGCAATTATGGTTGGCCGAA  800
      |||||||||||||||||||||||||||||||||||||||||||||||||||
  251 AspAspGluIleAsnLeuIleValLysGlyGlyAsnTyrGlyTrpProAs  267

  801 TGTAGCAGGTTATAAAGATGATAGTGGCTATGCTTATGCAAATTATTCAG  850
      |||||||||||||||||||||||||||||||||||||||||||||||||||
  268 nValAlaGlyTyrLysAspAspSerGlyTyrAlaTyrAlaAsnTyrSerA  284

  851 CAGCAGCCAATAAGTCAATTAAGGATTTAGCTCAAAATGGAGTAAAAGTA  900
      |||||||||||||||||||||||||||||||||||||||||||||||||||
  285 laAlaAlaAsnLysSerIleLysAspLeuAlaGlnAsnGlyValLysVal  300

  901 GCCGCAGGGGTCCCTGTGACGAAAGAATCTGAATGGACTGGTAAAAACTT  950
      |||||||||||||||||||||||||||||||||||||||||||||||||||
  301 AlaAlaGlyValProValThrLysGluSerGluTrpThrGlyLysAsnPh  317

  951 TGTCCCACCATTAAAAACTTTATATACCGTTCAAGATACCTACAACTATA  1000
      |||||||||||||||||||||||||||||||||||||||||||||||||||
  318 eValProProLeuLysThrLeuTyrThrValGlnAspThrTyrAsnTyrA  334

 1001 ACGATCCAACTTGTGGAGAGATGACCTACATTTGCTGGCCAACAGTTGCA  1050
      |||||||||||||||||||||||||||||||||||||||||||||||||||
  335 snAspProThrCysGlyGluMetThrTyrIleCysTrpProThrValAla  350

 1051 CCGTCATCTGCCTATGTCTATAAGGGCGGTAAAAAAGCAATTACTGGTTG  1100
      |||||||||||||||||||||||||||||||||||||||||||||||||||
  351 ProSerSerAlaTyrValTyrLysGlyGlyLysLysAlaIleThrGlyTr  367

 1101 GGAAAATACATTATTGGTTCCATCTTTAAAACGTGGTGTCATTTTCCGTA  1150
      |||||||||||||||||||||||||||||||||||||||||||||||||||
  368 pGluAsnThrLeuLeuValProSerLeuLysArgGlyValIlePheArgI  384

 1151 TTAAGTTAGATCCAACTTATAGCACTACTTATGATGACGCTGTACCGATG  1200
      |||||||||||||||||||||||||||||||||||||||||||||||||||
  385 leLysLeuAspProThrTyrSerThrThrTyrAspAspAlaValProMet  400

 1201 TTTAAGAGCAACAACCGTTATCGTGATGTGATTGCAAGTCCAGATGGGAA  1250
      |||||||||||||||||||||||||||||||||||||||||||||||||||
  401 PheLysSerAsnAsnArgTyrArgAspValIleAlaSerProAspGlyAs  417

 1251 TGTCTTATATGTATTAACTGATACTGCCGGAAATGTCCAAAAAGATGATG  1300
      |||||||||||||||||||||||||||||||||||||||||||||||||||
  418 nValLeuTyrValLeuThrAspThrAlaGlyAsnValGlnLysAspAspG  434

 1301 GCTCAGTAACAAATACATTAGAAAACCCAGGATCTCTCATTAAGTTCACC  1350
      |||||||||||||||||||||||||||||||||||||||||||||||||||
  435 lySerValThrAsnThrLeuGluAsnProGlySerLeuIleLysPheThr  450

 1351 TATAAGGCTAAG  1362
      ||||||||||||
  451 TyrLysAlaLys  454
```

Figure 2: Amino acid sequences of A. calcoaceticus (top) and
A. baumannii (bottom)

```
  1 DVPLTPSQFAKAKSENFDKKVILSNLNKPHALLWGPDNQIWLTERATGKI  50
    |:|||| .||||||| .|||||||||||||||||||||||||||||||||
  1 DIPLTPAQFAKAKTENFDKKVILSNLNKPHALLWGPDNQIWLTERATGKI  50

 51 LRVNPESGSVKTVFQVPEIVNDADGQNGLLGFAFHPDFKNNPYIYISGTF 100
    |||||  |||  |||||||||||| .|||||||||||||||| .||||||||
 51 LRVNPVSGSAKTVFQVPEIVSDADGQNGLLGFAFHPDFKHNPYIYISGTF 100

101 KNPKSTDKELPNQTIIRRYTYNKSTDTLEKPVDLLAGLPSSKDHQSGRLV 150
    |||||||||||||||||||||||| .||| |||:||:||||||||||||||
101 KNPKSTDKELPNQTIIRRYTYNKTTDTFEKPIDLIAGLPSSKDHQSGRLV 150

151 IGPDQKIYYTIGDQGRNQLAYLFLPNQAQHTPTQQELNGKDYHTYMGKVL 200
    ||||||||||||||||||||||||| ||||||||||||| |||||||||||
151 IGPDQKIYYTIGDQGRNQLAYLFLSNQAQHTPTQQELNSKDYHTYMGKVL 200

201 RLNLDGSIPKDNPSFNGVVSHIYTLGHRNPQGLAFTPNGKLLQSEQGPNS 250
    ||||||||||||||||||||||||||||||||||| |||||||||||||||
201 RLNLDGSIPKDNPSFNGVVSHIYTLGHRNPQGLAFAPNGKLLQSEQGPNS 250

251 DDEINLIVKGGNYGWPNVAGYKDDSGYAYANYSAAANKS.IKDLAQNGVK 299
    |||||| : .|||||||||||||||||||||||||||| ||| ||||||||:|
251 DDEINLVLKGGNYGWPNVAGYKDDSGYAYANYSAATNKSQIKDLAQNGIK 300

300 VAAGVPVTKESEWTGKNFVPPLKTLYTVQDTYNYNDPTCGEMTYICWPTV 349
    || |||||||||||||||||||||||||||||||||||||| |||||||
301 VATGVPVTKESEWTGKNFVPPLKTLYTVQDTYNYNDPTCGEMAYICWPTV 350

350 APSSAYVYKGGKKAITGWENTLLVPSLKRGVIFRIKLDPTYSTTYDDAVP 399
    ||||||| |||||| ||||||||||||||||||||||||||||| |||:|
351 APSSAYVYTGGKKAIPGWENTLLVPSLKRGVIFRIKLDPTYSTTLDDAIP 400

400 MFKSNNRYRDVIASPDGNVLYVLTDTAGNVQKDDGSVTNTLENPGSLIKF 449
    |||||||||||||||:|| |||||||||||||||||||||| .|||||||||
401 MFKSNNRYRDVIASPEGNTLYVLTDTAGNVQKDDGSVTHTLENPGSLIKF 450

450 TYKAK 454
    || |
451 TYNGK 455
```

Figure 3: Schematic diagram of the plasmide with gene for s-GDH (pACSGDH)

Figure 4: Nucleotide (DNA) sequence of the pACSGDH vector

```
   1   CACTAACTGA TTACGCACCG CATGTAACCG TTTTCAATCT GTGAGTAAAT
  51   TCACAGTTTA TTAACATTGT GATAGCTATG ATGACAACGT TTGTCGCACT
 101   GTAACTAACG TGTAACAGTT AGTTGTCAGT TTTGCTGGGG TATTTCGCTT
 151   ATAAAAACCG TTATCACAAT ATCCCGCGAC TACCGGACAA AAATAAAGAG
 201   TTGAATAAGA GCTTATCCCA TTAGGGCTAT TTTACTTGCC ATTTTGGACC
 251   TGGGCAGTGC TCGCCAAAAC GCGTTAGCGT TTTGAACGCG CTAGCGGCGG
 301   CCCGAAGGGC GAGCGTAGCG AGTCAAACCT CACGTACTAC GTGTACGCTC
 351   CGGTTTTTGC GCGCTGTCCG TGTCCAAACT GCTGCGCCAA TAACGCCTGG
 401   TGGGATAGGC TCTAAATACG CTTCGGCGTT CAGTAACACG CGTTAACGTG
 451   CTGAACAGCC GGGCATTTTT TTACGCTATA CCCTACATAA TAAAACCGGA
 501   GCTACCATGA ATAAGAAGGT ACTGACCCTT TCTGCCGTGA TGGCAAGTCT
 551   GTTATTCGGC GCGCACGCGC ATGCCGCCGA TGTTCCTCTA ACTCCATCTC
 601   AATTTGCTAA AGCGAAATCA GAGAACTTTG ACAAGAAAGT TATTCTATCT
 651   AATCTAAATA AGCCGCACGC GTTGTTATGG GGACCAGATA ATCAAATTTG
 701   GTTAACTGAG CGAGCAACAG GTAAGATTCT AAGAGTTAAT CCAGAGTCGG
 751   GTAGTGTAAA AACAGTTTTT CAGGTACCAG AGATTGTCAA TGATGCTGAT
 801   GGGCAGAATG GTTTATTAGG TTTTGCCTTC CATCCTGATT TTAAAAATAA
 851   TCCTTATATC TATATTTCAG GTACATTTAA AAATCCGAAA TCTACAGATA
 901   AAGAATTACC GAACCAAACG ATTATTCGTC GTTATACCTA TAATAAATCA
 951   ACAGATACGC TCGAGAAGCC AGTCGATTTA TTAGCAGGAT TACCTTCATC
1001   AAAAGACCAT CAGTCAGGTC GTCTTGTCAT TGGGCCAGAT CAAAAGATTT
1051   ATTATACGAT TGGTGACCAA GGGCGTAACC AGCTTGCTTA TTTGTTCTTG
1101   CCAAATCAAG CACAACATAC GCCAACTCAA CAAGAACTGA ATGGTAAAGA
1151   CTATCACACC TATATGGGTA AAGTACTACG CTTAAATCTT GATGGAAGTA
1201   TTCCAAAGGA TAATCCAAGT TTTAACGGGG TGGTTAGCCA TATTTATACA
1251   CTTGGACATC GTAATCCGCA GGGCTTAGCA TTCACTCCAA ATGGTAAATT
1301   ATTGCAGTCT GAACAAGGCC CAAACTCTGA CGATGAAATT AACCTCATTG
1351   TCAAAGGTGG CAATTATGGT TGGCCGAATG TAGCAGGTTA TAAAGATGAT
1401   AGTGGCTATG CTTATGCAAA TTATTCAGCA GCAGCCAATA AGTCAATTAA
1451   GGATTTAGCT CAAAATGGAG TAAAAGTAGC CGCAGGGGTC CCTGTGACGA
1501   AAGAATCTGA ATGGACTGGT AAAAACTTTG TCCCACCATT AAAAACTTTA
```

Figure 4: Continued (second out of three pages)

```
     1551  TATACCGTTC AAGATACCTA CAACTATAAC GATCCAACTT GTGGAGAGAT
5
     1601  GACCTACATT TGCTGGCCAA CAGTTGCACC GTCATCTGCC TATGTCTATA

     1651  AGGGCGGTAA AAAAGCAATT ACTGGTTGGG AAAATACATT ATTGGTTCCA

10
     1701  TCTTTAAAAC GTGGTGTCAT TTTCCGTATT AAGTTAGATC CAACTTATAG

     1751  CACTACTTAT GATGACGCTG TACCGATGTT TAAGAGCAAC AACCGTTATC

     1801  GTGATGTGAT TGCAAGTCCA GATGGGAATG TCTTATATGT ATTAACTGAT
15
     1851  ACTGCCGGAA ATGTCCAAAA AGATGATGGC TCAGTAACAA ATACATTAGA

     1901  AAACCCAGGA TCTCTCATTA AGTTCACCTA TAAGGCTAAG TAATACAGTC

20
     1951  GCATTAAAAA ACCGATCTAT AAAGATCGGT TTTTTTAGTT TTAGAAAAGA

     2001  ATTCACTGGC CGTCGTTTTA CAACGTCGTG ACTGGGAAAA CCCTGGCGTT

     2051  ACCCAACTTA ATCGCCTTGC AGCACATCCC CCTTTCGCCA GCTGGCGTAA
25
     2101  TAGCGAAGAG GCCCGCACCG ATCGCCCTTC CCAACAGTTG CGCAGCCTGA

     2151  ATGGCGAATG GCGCCTGATG CGGTATTTTC TCCTTACGCA TCTGTGCGGT

30
     2201  ATTTCACACC GCATATGGTG CACTCTCAGT ACAATCTGCT CTGATGCCGC

     2251  ATAGTTAAGC CAGCCCCGAC ACCCGCCAAC ACCCGCTGAC GCGCCCTGAC

     2301  GGGCTTGTCT GCTCCCGGCA TCCGCTTACA GACAAGCTGT GACCGTCTCC
35
     2351  GGGAGCTGCA TGTGTCAGAG GTTTTCACCG TCATCACCGA AACGCGCGAG

     2401  ACGAAAGGGC CTCGTGATAC GCCTATTTTT ATAGGTTAAT GTCATGATAA

40
     2451  TAATGGTTTC TTAGACGTCA GGTGGCACTT TTCGGGGAAA TGTGCGCGGA

     2501  ACCCCTATTT GTTTATTTTT CTAAATACAT TCAAATATGT ATCCGCTCAT

     2551  GAGACAATAA CCCTGATAAA TGCTTCAATA ATATTGAAAA AGGAAGAGTA
45
     2601  TGAGTATTCA ACATTTCCGT GTCGCCCTTA TTCCCTTTTT TGCGGCATTT

     2651  TGCCTTCCTG TTTTTGCTCA CCCAGAAACG CTGGTGAAAG TAAAAGATGC

50
     2701  TGAAGATCAG TTGGGTGCAC GAGTGGGTTA CATCGAACTG GATCTCAACA

     2751  GCGGTAAGAT CCTTGAGAGT TTTCGCCCCG AAGAACGTTT TCCAATGATG

     2801  AGCACTTTTA AAGTTCTGCT ATGTGGCGCG GTATTATCCC GTATTGACGC
55
     2851  CGGGCAAGAG CAACTCGGTC GCCGCATACA CTATTCTCAG AATGACTTGG

     2901  TTGAGTACTC ACCAGTCACA GAAAAGCATC TTACGGATGG CATGACAGTA

60
     2951  AGAGAATTAT GCAGTGCTGC CATAACCATG AGTGATAACA CTGCGGCCAA

     3001  CTTACTTCTG ACAACGATCG GAGGACCGAA GGAGCTAACC GCTTTTTTGC

     3051  ACAACATGGG GGATCATGTA ACTCGCCTTG ATCGTTGGGA ACCGGAGCTG
```

Figure 4: Continued (third and last page)

```
3101  AATGAAGCCA TACCAAACGA CGAGCGTGAC ACCACGATGC CTGTAGCAAT

3151  GGCAACAACG TTGCGCAAAC TATTAACTGG CGAACTACTT ACTCTAGCTT

3201  CCCGGCAACA ATTAATAGAC TGGATGGAGG CGGATAAAGT TGCAGGACCA

3251  CTTCTGCGCT CGGCCCTTCC GGCTGGCTGG TTTATTGCTG ATAAATCTGG

3301  AGCCGGTGAG CGTGGGTCTC GCGGTATCAT TGCAGCACTG GGGCCAGATG

3351  GTAAGCCCTC CCGTATCGTA GTTATCTACA CGACGGGGAG TCAGGCAACT

3401  ATGGATGAAC GAAATAGACA GATCGCTGAG ATAGGTGCCT CACTGATTAA

3451  GCATTGGTAA CTGTCAGACC AAGTTTACTC ATATATACTT TAGATTGATT

3501  TAAAACTTCA TTTTTAATTT AAAAGGATCT AGGTGAAGAT CCTTTTTGAT

3551  AATCTCATGA CCAAAATCCC TTAACGTGAG TTTTCGTTCC ACTGAGCGTC

3601  AGACCCCGTA GAAAAGATCA AAGGATCTTC TTGAGATCCT TTTTTTCTGC

3651  GCGTAATCTG CTGCTTGCAA ACAAAAAAAC CACCGCTACC AGCGGTGGTT

3701  TGTTTGCCGG ATCAAGAGCT ACCAACTCTT TTTCCGAAGG TAACTGGCTT

3751  CAGCAGAGCG CAGATACCAA ATACTGTCCT TCTAGTGTAG CCGTAGTTAG

3801  GCCACCACTT CAAGAACTCT GTAGCACCGC CTACATACCT CGCTCTGCTA

3851  ATCCTGTTAC CAGTGGCTGC TGCCAGTGGC GATAAGTCGT GTCTTACCGG

3901  GTTGGACTCA AGACGATAGT TACCGGATAA GGCGCAGCGG TCGGGCTGAA

3951  CGGGGGGTTC GTGCACACAG CCCAGCTTGG AGCGAACGAC CTACACCGAA

4001  CTGAGATACC TACAGCGTGA GCTATGAGAA AGCGCCACGC TTCCCGAAGG

4051  GAGAAAGGCG GACAGGTATC CGGTAAGCGG CAGGGTCGGA ACAGGAGAGC

4101  GCACGAGGGA GCTTCCAGGG GGAAACGCCT GGTATCTTTA TAGTCCTGTC

4151  GGGTTTCGCC ACCTCTGACT TGAGCGTCGA TTTTTGTGAT GCTCGTCAGG

4201  GGGGCGGAGC CTATGGAAAA ACGCCAGCAA CGCGGCCTTT TTACGGTTCC

4251  TGGCCTTTTG CTGGCCTTTT GCTCACATGT TCTTTCCTGC GTTATCCCCT

4301  GATTCTGTGG ATAACCGTAT TACCGCCTTT GAGTGAGCTG ATACCGCTCG

4351  CCGCAGCCGA ACGACGGGGC CCG
```

SEQUENCE LISTING

<110> F. Hoffmann-La Roche AG
      Roche Diagnostics GmbH

<120> New forms of soluble Pyrroloquinoline Quinone-dependent
      Glucose Dehydrogenase

<130> 19139 WO

<140>
<141>

<150> EP 00123512.6
<151> 2000-10-27

<150> EP 00127294.7
<151> 2000-12-19

<160> 25

<170> PatentIn Ver. 2.1

<210> 1
<211> 7
<212> PRT
<213> Acinetobacter calcoaceticus

<400> 1
Trp Pro Xaa Val Ala Pro Ser
 1   5

<210> 2
<211> 7
<212> PRT
<213> Acinetobacter calcoaceticus

<400> 2
Thr Ala Gly Xaa Val Gln Lys
 1   5

<210> 3
<211> 7
<212> PRT
<213> Acinetobacter calcoaceticus

<400> 3
Ala Asp Gly Xaa Asn Gly Leu
 1   5

<210> 4
<211> 26

```
      <212> DNA
      <213> Artificial Sequence

      <220>
5     <223> Description of Artificial Sequence:sense primer
            GF23

      <400> 4
      cgcgcacgcg catgccgccg atgttc                              26
10

      <210> 5
      <211> 23
      <212> DNA
15    <213> Artificial Sequence

      <220>
      <223> Description of Artificial Sequence:antisense
            primer GR23
20
      <400> 5
      gacggccagt gaattctttt cta                                 23

25    <210> 6
      <211> 20
      <212> DNA
      <213> Artificial Sequence

30    <220>
      <223> Description of Artificial Sequence:sense primer
            GDH F2

      <400> 6
35    ttaacgtgct gaacagccgg                                     20

      <210> 7
      <211> 20
40    <212> DNA
      <213> Artificial Sequence

      <220>
      <223> Description of Artificial Sequence:sense primer
45          GDH F3

      <400> 7
      gatgctgatg ggcagaatgg                                     20
50
      <210> 8
      <211> 20
      <212> DNA
      <213> Artificial Sequence
55
```

```
<220>
<223> Description of Artificial Sequence:sense primer
     GDH F4

<400> 8
atatgggtaa agtactacgc                                    20


<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:sense primer
     GDH F5

<400> 9
acgatccaac ttgtggagag                                    20


<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:antisense
     primer GDH R1

<400> 10
cgattaagtt gggtaacgcc                                    20


<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:antisense
     primer GDH R2

<400> 11
atacggaaaa tgacaccacg                                    20


<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:antisende
     primer GDH R3
```

- 4 -

```
<400> 12
gggccttgtt cagactgcaa                                                20
```

5

```
<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence
```

10

```
<220>
<223> Description of Artificial Sequence:antisense
      primer GDH R4
```

15
```
<400> 13
caagacgacc tgactgatgg                                                20
```

```
<210> 14
<211> 20
20   <212> DNA
<213> Artificial Sequence
```

```
<220>
25   <223> Description of Artificial Sequence:antisense
      primer GDH  R5
```

```
<400> 14
cataacaacg cgtgcggctt                                                20
```
30

```
<210> 15
<211> 29
<212> DNA
35   <213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence:sense primer
      EGF
```
40
```
<400> 15
tccaacttgt ggannnatga cctacattt                                      29
```

45   `<210> 16`
```
<211> 29
<212> DNA
<213> Artificial Sequence
```

50   `<220>`
```
<223> Description of Artificial Sequence:antisense
      primer EGR
```

```
<400> 16
55   aaatgtaggt catnnntcca caagttgga                                     29
```

```
     <210> 17
     <211> 29
  5  <212> DNA
     <213> Artificial Sequence

     <220>
     <223> Description of Artificial Sequence:sense primer
 10       TSF

     <400> 17
     catttgctgg ccannngttg caccgtcat                                29

 15
     <210> 18
     <211> 29
     <212> DNA
     <213> Artificial Sequence
 20
     <220>
     <223> Description of Artificial Sequence:antisense
          primer TSR

 25  <400> 18
     atgacggtgc aacnnntggc cagcaaatg                                29


     <210> 19
 30  <211> 29
     <212> DNA
     <213> Artificial Sequence

     <220>
 35  <223> Description of Artificial Sequence:sense primer
          NHF

     <400> 19
     tactggttgg gaannnacat tattggttc                                29
 40

     <210> 20
     <211> 29
     <212> DNA
 45  <213> Artificial Sequence

     <220>
     <223> Description of Artificial Sequence:antisense
          primer NHR
 50
     <400> 20
     gaaccaataa tgtnnnttcc caaccagta                                29


 55  <210> 21
```

```
        <211> 29
        <212> DNA
        <213> Artificial Sequence

  5     <220>
        <223> Description of Artificial Sequence:sense primer
              SNF

        <400> 21
 10     tgatgtgatt gcannnccag atgggaatg                          29


        <210> 22
        <211> 29
 15     <212> DNA
        <213> Artificial Sequence


        <220>
        <223> Description of Artificial Sequence:antisense
 20           primer SNR

        <400> 22
        cattcccatc tggnnntgca atcacatca                          29

 25
        <210> 23
        <211> 1362
        <212> DNA
        <213> Acinetobacter calcoaceticus
 30
        <220>
        <221> CDS
        <222> (1)..(1362)

 35     <400> 23
        gat gtt cct cta act cca tct caa ttt gct aaa gcg aaa tca gag aac   48
        Asp Val Pro Leu Thr Pro Ser Gln Phe Ala Lys Ala Lys Ser Glu Asn
          1               5                  10                  15

 40     ttt gac aag aaa gtt att cta tct aat cta aat aag ccg cac gcg ttg   96
        Phe Asp Lys Lys Val Ile Leu Ser Asn Leu Asn Lys Pro His Ala Leu
                     20                  25                  30

        tta tgg gga cca gat aat caa att tgg tta act gag cga gca aca ggt   144
 45     Leu Trp Gly Pro Asp Asn Gln Ile Trp Leu Thr Glu Arg Ala Thr Gly
                 35                  40                  45

        aag att cta aga gtt aat cca gag tcg ggt agt gta aaa aca gtt ttt   192
        Lys Ile Leu Arg Val Asn Pro Glu Ser Gly Ser Val Lys Thr Val Phe
 50          50                  55                  60

        cag gta cca gag att gtc aat gat gct gat ggg cag aat ggt tta tta   240
        Gln Val Pro Glu Ile Val Asn Asp Ala Asp Gly Gln Asn Gly Leu Leu
             65                  70                  75                  80
 55
```

- 7 -

```
      ggt ttt gcc ttc cat cct gat ttt aaa aat aat cct tat atc tat att   288
      Gly Phe Ala Phe His Pro Asp Phe Lys Asn Asn Pro Tyr Ile Tyr Ile
                      85              90              95

 5    tca ggt aca ttt aaa aat ccg aaa tct aca gat aaa gaa tta ccg aac   336
      Ser Gly Thr Phe Lys Asn Pro Lys Ser Thr Asp Lys Glu Leu Pro Asn
                  100             105             110

10    caa acg att att cgt cgt tat acc tat aat aaa tca aca gat acg ctc   384
      Gln Thr Ile Ile Arg Arg Tyr Thr Tyr Asn Lys Ser Thr Asp Thr Leu
                  115             120             125

      gag aag cca gtc gat tta tta gca gga tta cct tca tca aaa gac cat   432
      Glu Lys Pro Val Asp Leu Leu Ala Gly Leu Pro Ser Ser Lys Asp His
15                130             135             140

      cag tca ggt cgt ctt gtc att ggg cca gat caa aag att tat tat acg   480
      Gln Ser Gly Arg Leu Val Ile Gly Pro Asp Gln Lys Ile Tyr Tyr Thr
          145             150             155             160
20
      att ggt gac caa ggg cgt aac cag ctt gct tat ttg ttc ttg cca aat   528
      Ile Gly Asp Gln Gly Arg Asn Gln Leu Ala Tyr Leu Phe Leu Pro Asn
                      165             170             175

25    caa gca caa cat acg cca act caa caa gaa ctg aat ggt aaa gac tat   576
      Gln Ala Gln His Thr Pro Thr Gln Gln Glu Leu Asn Gly Lys Asp Tyr
                      180             185             190

      cac acc tat atg ggt aaa gta cta cgc tta aat ctt gat gga agt att   624
30    His Thr Tyr Met Gly Lys Val Leu Arg Leu Asn Leu Asp Gly Ser Ile
                  195             200             205

      cca aag gat aat cca agt ttt aac ggg gtg gtt agc cat att tat aca   672
      Pro Lys Asp Asn Pro Ser Phe Asn Gly Val Val Ser His Ile Tyr Thr
35        210             215             220

      ctt gga cat cgt aat ccg cag ggc tta gca ttc act cca aat ggt aaa   720
      Leu Gly His Arg Asn Pro Gln Gly Leu Ala Phe Thr Pro Asn Gly Lys
      225             230             235             240
40
      tta ttg cag tct gaa caa ggc cca aac tct gac gat gaa att aac ctc   768
      Leu Leu Gln Ser Glu Gln Gly Pro Asn Ser Asp Asp Glu Ile Asn Leu
                      245             250             255

45    att gtc aaa ggt ggc aat tat ggt tgg ccg aat gta gca ggt tat aaa   816
      Ile Val Lys Gly Gly Asn Tyr Gly Trp Pro Asn Val Ala Gly Tyr Lys
                  260             265             270

      gat gat agt ggc tat gct tat gca aat tat tca gca gca gcc aat aag   864
50    Asp Asp Ser Gly Tyr Ala Tyr Ala Asn Tyr Ser Ala Ala Ala Asn Lys
                  275             280             285

      tca att aag gat tta gct caa aat gga gta aaa gta gcc gca ggg gtc   912
      Ser Ile Lys Asp Leu Ala Gln Asn Gly Val Lys Val Ala Ala Gly Val
55        290             295             300
```

- 8 -

```
     cct gtg acg aaa gaa tct gaa tgg act ggt aaa aac ttt gtc cca cca     960
     Pro Val Thr Lys Glu Ser Glu Trp Thr Gly Lys Asn Phe Val Pro Pro
     305             310                 315                 320
  5

     tta aaa act tta tat acc gtt caa gat acc tac aac tat aac gat cca    1008
     Leu Lys Thr Leu Tyr Thr Val Gln Asp Thr Tyr Asn Tyr Asn Asp Pro
                     325                 330                 335

 10  act tgt gga gag atg acc tac att tgc tgg cca aca gtt gca ccg tca    1056
     Thr Cys Gly Glu Met Thr Tyr Ile Cys Trp Pro Thr Val Ala Pro Ser
                 340                 345                 350

     tct gcc tat gtc tat aag ggc ggt aaa aaa gca att act ggt tgg gaa    1104
 15  Ser Ala Tyr Val Tyr Lys Gly Gly Lys Lys Ala Ile Thr Gly Trp Glu
             355                 360                 365

     aat aca tta ttg gtt cca tct tta aaa cgt ggt gtc att ttc cgt att    1152
     Asn Thr Leu Leu Val Pro Ser Leu Lys Arg Gly Val Ile Phe Arg Ile
 20      370                 375                 380

     aag tta gat cca act tat agc act act tat gat gac gct gta ccg atg    1200
     Lys Leu Asp Pro Thr Tyr Ser Thr.Thr Tyr Asp Asp Ala Val Pro Met
     385                 390                 395                 400
 25

     ttt aag agc aac aac cgt tat cgt gat gtg att gca agt cca gat ggg    1248
     Phe Lys Ser Asn Asn Arg Tyr Arg Asp Val Ile Ala Ser Pro Asp Gly
                     405                 410                 415

 30  aat gtc tta tat gta tta act gat act gcc gga aat gtc caa aaa gat    1296
     Asn Val Leu Tyr Val Leu Thr Asp Thr Ala Gly Asn Val Gln Lys Asp
                 420                 425                 430

     gat ggc tca gta aca aat aca tta gaa aac cca gga tct ctc att aag    1344
 35  Asp Gly Ser Val Thr Asn Thr Leu Glu Asn Pro Gly Ser Leu Ile Lys
             435                 440                 445

     ttc acc tat aag gct aag                                            1362
     Phe Thr Tyr Lys Ala Lys
 40      450


     <210> 24
     <211> 454
 45  <212> PRT
     <213> Acinetobacter calcoaceticus

     <400> 24
     Asp Val Pro Leu Thr Pro Ser Gln Phe Ala Lys Ala Lys Ser Glu Asn
 50   1               5                   10                  15

     Phe Asp Lys Lys Val Ile Leu Ser Asn Leu Asn Lys Pro His Ala Leu
                     20                  25                  30

 55  Leu Trp Gly Pro Asp Asn Gln Ile Trp Leu Thr Glu Arg Ala Thr Gly
```

- 9 -

```
                 35                    40                    45
        Lys Ile Leu Arg Val Asn Pro Glu Ser Gly Ser Val Lys Thr Val Phe
                50                    55                    60
 5
        Gln Val Pro Glu Ile Val Asn Asp Ala Asp Gly Gln Asn Gly Leu Leu
                65                    70                    75                    80
        Gly Phe Ala Phe His Pro Asp Phe Lys Asn Asn Pro Tyr Ile Tyr Ile
10                              85                    90                    95
        Ser Gly Thr Phe Lys Asn Pro Lys Ser Thr Asp Lys Glu Leu Pro Asn
                        100                   105                   110
15      Gln Thr Ile Ile Arg Arg Tyr Thr Tyr Asn Lys Ser Thr Asp Thr Leu
                        115                   120                   125
        Glu Lys Pro Val Asp Leu Leu Ala Gly Leu Pro Ser Ser Lys Asp His
                130                   135                   140
20      Gln Ser Gly Arg Leu Val Ile Gly Pro Asp Gln Lys Ile Tyr Tyr Thr
        145                   150                   155                   160
        Ile Gly Asp Gln Gly Arg Asn Gln Leu Ala Tyr Leu Phe Leu Pro Asn
25                              165                   170                   175
        Gln Ala Gln His Thr Pro Thr Gln Gln Glu Leu Asn Gly Lys Asp Tyr
                        180                   185                   190
        His Thr Tyr Met Gly Lys Val Leu Arg Leu Asn Leu Asp Gly Ser Ile
30                      195                   200                   205
        Pro Lys Asp Asn Pro Ser Phe Asn Gly Val Val Ser His Ile Tyr Thr
                210                   215                   220
35      Leu Gly His Arg Asn Pro Gln Gly Leu Ala Phe Thr Pro Asn Gly Lys
        225                   230                   235                   240
        Leu Leu Gln Ser Glu Gln Gly Pro Asn Ser Asp Asp Glu Ile Asn Leu
40                      245                   250                   255
        Ile Val Lys Gly Gly Asn Tyr Gly Trp Pro Asn Val Ala Gly Tyr Lys
                        260                   265                   270
45      Asp Asp Ser Gly Tyr Ala Tyr Ala Asn Tyr Ser Ala Ala Ala Asn Lys
                        275                   280                   285
        Ser Ile Lys Asp Leu Ala Gln Asn Gly Val Lys Val Ala Ala Gly Val
50                      290                   295                   300
        Pro Val Thr Lys Glu Ser Glu Trp Thr Gly Lys Asn Phe Val Pro Pro
        305                   310                   315                   320
        Leu Lys Thr Leu Tyr Thr Val Gln Asp Thr Tyr Asn Tyr Asn Asp Pro
55                      325                   330                   335
```

- 10 -

```
          Thr Cys Gly Glu Met Thr Tyr Ile Cys Trp Pro Thr Val Ala Pro Ser
                  340                 345                 350

    5     Ser Ala Tyr Val Tyr Lys Gly Gly Lys Lys Ala Ile Thr Gly Trp Glu
                      355                 360                 365

          Asn Thr Leu Leu Val Pro Ser Leu Lys Arg Gly Val Ile Phe Arg Ile
                  370                 375                 380
   10
          Lys Leu Asp Pro Thr Tyr Ser Thr Thr Tyr Asp Asp Ala Val Pro Met
          385                 390                 395                 400

          Phe Lys Ser Asn Asn Arg Tyr Arg Asp Val Ile Ala Ser Pro Asp Gly
   15                         405                 410                 415

          Asn Val Leu Tyr Val Leu Thr Asp Thr Ala Gly Asn Val Gln Lys Asp
                          420                 425                 430

   20     Asp Gly Ser Val Thr Asn Thr Leu Glu Asn Pro Gly Ser Leu Ile Lys
                      435                 440                 445

          Phe Thr Tyr Lys Ala Lys
                  450
   25


          <210> 25
          <211> 4373
   30     <212> DNA
          <213> Artificial Sequence

          <220>
          <223> Description of Artificial Sequence:vector pACSGDH
   35
          <400> 25
          cactaactga ttacgcaccg catgtaaccg ttttcaatct gtgagtaaat tcacagttta 60
          ttaacattgt gatagctatg atgacaacgt ttgtcgcact gtaactaacg tgtaacagtt 120
          agttgtcagt tttgctgggg tatttcgctt ataaaaaccg ttatcacaat atcccgcgac 180
   40     taccggacaa aaataaagag ttgaataaga gcttatccca ttagggctat tttacttgcc 240
          attttggacc tgggcagtgc tcgccaaaac gcgttagcgt tttgaacgcg ctagcggcgg 300
          cccgaagggc gagcgtagcg agtcaaacct cacgtactac gtgtacgctc cggtttttgc 360
          gcgctgtccg tgtccaaact gctgcgccaa taacgcctgg tgggataggc tctaaatacg 420
          cttcggcgtt cagtaacacg cgttaacgtg ctgaacagcc gggcatttt ttacgctata 480
   45     ccctacataa taaaaccgga gctaccatga ataagaaggt actgaccctt tctgccgtga 540
          tggcaagtct gttattcggc gcgcacgcgc atgccgccga tgttcctcta actccatctc 600
          aatttgctaa agcgaaatca gagaactttg acaagaaagt tattctatct aatctaaata 660
          agccgcacgc gttgttatgg ggaccagata atcaaatttg gttaactgag cgagcaacag 720
          gtaagattct aagagttaat ccagagtcgg gtagtgtaaa aacagttttt caggtaccag 780
   50     agattgtcaa tgatgctgat gggcagaatg gtttattagg ttttgccttc catcctgatt 840
          ttaaaaataa tccttatatc tatatttcag gtacatttaa aaatccgaaa tctacagata 900
          aagaattacc gaaccaaacg attattcgtc gttatccta taataaatca acagatacgc 960
          tcgagaagcc agtcgattta ttagcaggat taccttcatc aaaagaccat cagtcaggtc 1020
          gtcttgtcat tgggccagat caaaagattt attatacgat tggtgaccaa gggcgtaacc 1080
   55     agcttgctta tttgttcttg ccaaatcaag cacaacatac gccaactcaa caagaactga 1140
```

```
atggtaaaga ctatcacacc tatatgggta aagtactacg cttaaatctt gatggaagta  1200
ttccaaagga taatccaagt tttaacgggg tggttagcca tatttataca cttggacatc  1260
gtaatccgca gggcttagca ttcactccaa atggtaaatt attgcagtct gaacaaggcc  1320
caaactctga cgatgaaatt aacctcattg tcaaaggtgg caattatggt tggccgaatg  1380
tagcaggtta taaagatgat agtggctatg cttatgcaaa ttattcagca gcagccaata  1440
agtcaattaa ggatttagct caaaatggag taaaagtagc cgcagggrtc cctgtgacga  1500
aagaatctga atggactggt aaaaactttg tcccaccatt aaaaacttta tataccgttc  1560
aagatacccta caactataac gatccaactt gtggagagat gacctacatt tgctggccaa  1620
cagttgcacc gtcatctgcc tatgtctata agggcggtaa aaaagcaatt actggttggg  1680
aaaatacatt attggttcca tctttaaaac gtggtgtcat tttccgtatt aagttagatc  1740
caacttatag cactacttat gatgacgctg taccgatgtt taagagcaac aaccgttatc  1800
gtgatgtgat tgcaagtcca gatgggaatg tcttatatgt attaactgat actgccggaa  1860
atgtccaaaa agatgatggc tcagtaacaa atacattaga aaacccagga tctctcatta  1920
agttcaccta taaggctaag taatacagtc gcattaaaaa accgatctat aaagatcggt  1980
ttttttagtt ttagaaaaga attcactggc cgtcgtttta caacgtcgtg actgggaaaa  2040
ccctggcgtt acccaactta atcgccttgc agcacatccc cctttcgcca gctggcgtaa  2100
tagcgaagag gcccgcaccg atcgcccttc ccaacagttg cgcagcctga atggcgaatg  2160
gcgcctgatg cggtattttc tccttacgca tctgtgcggt atttcacacc gcatatggtg  2220
cactctcagt acaatctgct ctgatgccgc atagttaagc cagccccgac acccgccaac  2280
accgctgacg cgccctgacg ggcttgtct gctcccggca tccgcttaca gacaagctgt  2340
gaccgtctcc gggagctgca tgtgtcagag gttttcaccg tcatcaccga aacgcgcgag  2400
acgaaagggc ctcgtgatac gcctattttt ataggttaat gtcatgataa taatggtttc  2460
ttagacgtca ggtggcactt ttcggggaaa tgtgcgcgga accctatt gtttattttt  2520
ctaaatacat tcaaatatgt atccgctcat gagacaataa ccctgataaa tgcttcaata  2580
atattgaaaa aggaagagta tgagtattca acatttccgt gtcgccctta ttcccttttt  2640
tgcggcattt tgccttcctg tttttgctca cccagaaacg ctggtgaaag taaaagatgc  2700
tgaagatcag ttgggtgcac gagtgggtta catcgaactg gatctcaaca gcggtaagat  2760
ccttgagagt tttcgccccg aagaacgttt tccaatgatg agcactttta agttctgct  2820
atgtggcgcg gtattatccc gtattgacgc cgggcaagag caactcggtc gccgcataca  2880
ctattctcag aatgacttgg ttgagtactc accagtcaca gaaaagcatc ttacggatgg  2940
catgacagta agagaattat gcagtgctgc cataaccatg agtgataaca ctgcggccaa  3000
cttacttctg acaacgatcg gaggaccgaa ggagctaacc gcttttttgc acaacatggg  3060
ggatcatgta actcgccttg atcgttggga accggagctg aatgaagcca taccaaacga  3120
cgagcgtgac accacgatgc ctgtagcaat ggcaacaacg ttgcgcaaac tattaactgg  3180
cgaactactt actctagctt cccggcaaca attaatagac tggatggagg cggataaagt  3240
tgcaggacca cttctgcgct cggcccttcc ggctggctgg tttattgctg ataaatctgg  3300
agccggtgag cgtgggtctc gcggtatcat tgcagcactg gggccagatg gtaagccctc  3360
ccgtatcgta gttatctaca cgacggggag tcaggcaact atggatgaac gaaatagaca  3420
gatcgctgag ataggtgcct cactgattaa gcattggtaa ctgtcagacc aagtttactc  3480
atatatactt tagattgatt taaaacttca tttttaattt aaaaggatct aggtgaagat  3540
cctttttgat aatctcatga ccaaaatccc ttaacgtgag ttttcgttcc actgagcgtc  3600
agaccccgta gaaaagatca aaggatcttc ttgagatcct ttttttctgc gcgtaatctg  3660
ctgcttgcaa acaaaaaaac caccgctacc agcggtggtt tgtttgccgg atcaagagct  3720
accaactctt tttccgaagg taactggctt cagcagagcg cagataccaa atactgtcct  3780
tctagtgtag ccgtagttag gccaccactt caagaactct gtagcaccgc ctacatacct  3840
cgctctgcta atcctgttac cagtggctgc tgccagtggc gataagtcgt gtcttaccgg  3900
gttggactca agacgatagt taccggataa ggcgcagcgg tcgggctgaa cggggggttc  3960
gtgcacacag cccagcttgg agcgaacgac ctacaccgaa ctgagatacc tacagcgtga  4020
gctatgagaa agcgccacgc ttcccgaagg gagaaaggcg gacaggtatc cggtaagcgg  4080
cagggtcgga acaggagagc gcacgaggga gcttccaggg gaaacgcct ggtatcttta  4140
tagtcctgtc gggtttcgcc acctctgact tgagcgtcga ttttgtgat gctcgtcagg  4200
ggggcggagc ctatggaaaa acgccagcaa cgcggccttt ttacggttcc tggccttttg  4260
ctggcctttt gctcacatgt tctttcctgc gttatcccct gattctgtgg ataaccgtat  4320
taccgccttt gagtgagctg ataccgctcg ccgcagccga acgacgggc ccg          4373
```

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7   C12N15/53   C12N9/04   C12Q1/32   C12Q1/54   //(C12N9/04,
C12R1:01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7   C12N   C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category°	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	IGARASHI SATOSHI ET AL: "Construction and characterization of mutant water-soluble PQQ glucose dehydrogenases with altered Km values-Site-directed mutagenesis studies on the putative active site." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 264, no. 3, 2 November 1999 (1999-11-02), pages 820-824, XP000990137 ISSN: 0006-291X cited in the application abstract; tables 1,2 —/—	1-4,6-8, 28-30

[X] Further documents are listed in the continuation of box C.   [ ] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
18 March 2002	25/03/2002

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Espen, J

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
P,X	DATABASE WPI Section Ch, Week 200066 Derwent Publications Ltd., London, GB; Class B04, AN 2000-679762 XP002168297 & WO 00 66744 A (SODE K), 9 November 2000 (2000-11-09) abstract -& EP 1 176 202 A (SODE K) 30 January 2002 (2002-01-30) tables 3,4	1-4,6-8, 28-30
A	DATABASE WPI Section Ch, Week 200064 Derwent Publications Ltd., London, GB; Class B04, AN 2000-665126 XP002168296 & WO 00 61730 A (SODE K), 19 October 2000 (2000-10-19) abstract	
A	CLETON-JANSEN A-M ET AL: "CLONING, CHARACTERIZATION AND DNA SEQUENCING OF THE GENE ENCODING THE MR 50000 QUINOPROTEIN GLUCOSE DEHYDROGENASE FROM ACINETOBACTER CALCOACETICUS" MOLECULAR AND GENERAL GENETICS,SPRINGER VERLAG, BERLIN,DE, vol. 217, no. 2/03, June 1989 (1989-06), pages 430-436, XP000990490 ISSN: 0026-8925	